BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100-103. [PMID: 22281684 DOI: 10.1038/nature10868] [Cited by in Crossref: 1244] [Cited by in F6Publishing: 1090] [Article Influence: 124.4] [Reference Citation Analysis]
Number Citing Articles
1 Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N, Luo CS, Wu SM. The Role of EREG/EGFR Pathway in Tumor Progression. Int J Mol Sci 2021;22:12828. [PMID: 34884633 DOI: 10.3390/ijms222312828] [Reference Citation Analysis]
2 Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol. 2015;6:660-667. [PMID: 26697199 DOI: 10.3978/j.issn.2078-6891.2015.077] [Cited by in F6Publishing: 58] [Reference Citation Analysis]
3 Niepel M, Hafner M, Duan Q, Wang Z, Paull EO, Chung M, Lu X, Stuart JM, Golub TR, Subramanian A, Ma'ayan A, Sorger PK. Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nat Commun 2017;8:1186. [PMID: 29084964 DOI: 10.1038/s41467-017-01383-w] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
4 Yan Y, Hein AL, Greer PM, Wang Z, Kolb RH, Batra SK, Cowan KH. A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation. Oncogene 2015;34:2215-26. [PMID: 24909175 DOI: 10.1038/onc.2014.167] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
5 Miles DC, de Vries NA, Gisler S, Lieftink C, Akhtar W, Gogola E, Pawlitzky I, Hulsman D, Tanger E, Koppens M, Beijersbergen RL, van Lohuizen M. TRIM28 is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming. Stem Cells. 2017;35:147-157. [PMID: 27350605 DOI: 10.1002/stem.2453] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
6 Damato A, Iachetta F, Antonuzzo L, Nasti G, Bergamo F, Bordonaro R, Maiello E, Zaniboni A, Tonini G, Romagnani A, Berselli A, Normanno N, Pinto C. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). BMC Cancer 2020;20:822. [PMID: 32867715 DOI: 10.1186/s12885-020-07268-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Modugno F, Edwards RP. Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. Int J Gynecol Cancer 2012;22:S45-57. [PMID: 23013733 DOI: 10.1097/IGC.0b013e31826bd1f2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
8 Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. APMIS 2013;121:954-66. [DOI: 10.1111/apm.12152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
9 Amrane K, le Pennec R, Schick U, Metges JP, Abgral R. Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer. Clin Nucl Med 2020;45:707-8. [PMID: 32657876 DOI: 10.1097/RLU.0000000000003190] [Reference Citation Analysis]
10 Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. European Journal of Cancer 2015;51:587-94. [DOI: 10.1016/j.ejca.2015.01.054] [Cited by in Crossref: 284] [Cited by in F6Publishing: 258] [Article Influence: 40.6] [Reference Citation Analysis]
11 Tannock I, Hickman J. Molecular screening to select therapy for advanced cancer? Annals of Oncology 2019;30:661-3. [DOI: 10.1093/annonc/mdz088] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
12 Sartore-bianchi A, Loupakis F, Argilés G, Prager G. Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology 2016;27:1456-66. [DOI: 10.1093/annonc/mdw191] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
13 Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Flaherty KT, Bernards R, Lito P, Settleman J, McCormick F. Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. Clin Cancer Res 2019;25:7202-17. [PMID: 31515463 DOI: 10.1158/1078-0432.CCR-18-2779] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
14 Haq R, Fisher DE, Widlund HR. Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res 2014;20:2257-63. [PMID: 24610826 DOI: 10.1158/1078-0432.CCR-13-0898] [Cited by in Crossref: 52] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
15 Iizuka-Ohashi M, Watanabe M, Sukeno M, Morita M, Hoang NTH, Kuchimaru T, Kizaka-Kondoh S, Sowa Y, Sakaguchi K, Taguchi T, Sakai T. Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells. Oncotarget 2018;9:19597-612. [PMID: 29731968 DOI: 10.18632/oncotarget.24696] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
16 Pongor L, Kormos M, Hatzis C, Pusztai L, Szabó A, Győrffy B. A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients. Genome Med 2015;7:104. [PMID: 26474971 DOI: 10.1186/s13073-015-0228-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
17 Goel G. Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. Cancer Manag Res 2018;10:5895-908. [PMID: 30510457 DOI: 10.2147/CMAR.S162967] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Komatsu N, Fujita Y, Matsuda M, Aoki K. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells. Oncogene 2015;34:5607-16. [PMID: 25703330 DOI: 10.1038/onc.2015.16] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
19 Hölzel M, Bovier A, Tüting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer. 2013;13:365-376. [PMID: 23535846 DOI: 10.1038/nrc3498] [Cited by in Crossref: 166] [Cited by in F6Publishing: 142] [Article Influence: 18.4] [Reference Citation Analysis]
20 Girotti MR, Marais R. Deja Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov 2013;3:487-90. [PMID: 23658295 DOI: 10.1158/2159-8290.CD-13-0131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
21 Kreß JKC, Jessen C, Marquardt A, Hufnagel A, Meierjohann S. NRF2 Enables EGFR Signaling in Melanoma Cells. Int J Mol Sci 2021;22:3803. [PMID: 33916908 DOI: 10.3390/ijms22083803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Wang H, Zheng X, Fei T, Wang J, Li X, Liu Y, Zhang F. Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway. Clin Transl Med 2015;4:66. [PMID: 26220863 DOI: 10.1186/s40169-015-0066-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther 2017;17:951-64. [PMID: 28817982 DOI: 10.1080/14737140.2017.1369882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. Cell 2013;155:27-38. [PMID: 24074859 DOI: 10.1016/j.cell.2013.09.006] [Cited by in Crossref: 579] [Cited by in F6Publishing: 443] [Article Influence: 64.3] [Reference Citation Analysis]
26 Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, Pradines A, Santamaria D, Swalduz A, Ambrogio C, Novello S, Ortiz-cuaran S. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). Cancer Treatment Reviews 2022;103:102335. [DOI: 10.1016/j.ctrv.2021.102335] [Reference Citation Analysis]
27 Dey N, Williams C, Leyland-jones B, De P. Mutation matters in precision medicine: A future to believe in. Cancer Treatment Reviews 2017;55:136-49. [DOI: 10.1016/j.ctrv.2017.03.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
28 Ryan CJ, Bajrami I, Lord CJ. Synthetic Lethality and Cancer – Penetrance as the Major Barrier. Trends in Cancer 2018;4:671-83. [DOI: 10.1016/j.trecan.2018.08.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
29 Diez-cecilia E, Carson R, Kelly B, van Schaeybroeck S, Murray JT, Rozas I. Probing a 3,4′-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway. Bioorganic & Medicinal Chemistry Letters 2015;25:4287-92. [DOI: 10.1016/j.bmcl.2015.07.082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
30 Wei G, Gao N, Chen J, Fan L, Zeng Z, Gao G, Li L, Fang G, Hu K, Pang X, Fan HY, Clevers H, Liu M, Zhang X, Li D. Erk and MAPK signaling is essential for intestinal development through Wnt pathway modulation. Development 2020;147:dev185678. [PMID: 32747435 DOI: 10.1242/dev.185678] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Zota VE, Magliocco AM. Molecular Technologies in the Clinical Diagnostic Laboratory. Cancer Control 2015;22:142-51. [PMID: 26068758 DOI: 10.1177/107327481502200204] [Reference Citation Analysis]
32 Leto SM, Trusolino L. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) 2014;92:709-22. [PMID: 24811491 DOI: 10.1007/s00109-014-1161-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
33 Patel JN, Ersek JL, Kim ES. Lung cancer biomarkers, targeted therapies and clinical assays. Transl Lung Cancer Res 2015;4:503-14. [PMID: 26629419 DOI: 10.3978/j.issn.2218-6751.2015.06.02] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
34 Molina-Cerrillo J, San Román M, Pozas J, Alonso-Gordoa T, Pozas M, Conde E, Rosas M, Grande E, García-Bermejo ML, Carrato A. BRAF Mutated Colorectal Cancer: New Treatment Approaches. Cancers (Basel) 2020;12:E1571. [PMID: 32545884 DOI: 10.3390/cancers12061571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
35 Nakanishi Y, Diaz-Meco MT, Moscat J. Serrated Colorectal Cancer: The Road Less Travelled? Trends Cancer. 2019;5:742-754. [PMID: 31735291 DOI: 10.1016/j.trecan.2019.09.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
36 Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 2015;1855:104-121. [PMID: 25450577 DOI: 10.1016/j.bbcan.2014.09.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 122] [Article Influence: 8.4] [Reference Citation Analysis]
37 Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12:621-628. [PMID: 22845482 DOI: 10.1586/erm.12.46] [Cited by in Crossref: 111] [Cited by in F6Publishing: 108] [Article Influence: 11.1] [Reference Citation Analysis]
38 Gandolfi G, Sancisi V, Piana S, Ciarrocchi A. Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma. Int J Cancer 2015;137:1001-11. [PMID: 24828987 DOI: 10.1002/ijc.28976] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
39 Suzuki S, Matsusaka S, Hirai M, Shibata H, Takagi K, Mizunuma N, Hatake K. A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. Int J Oncol 2015;47:97-105. [PMID: 25936694 DOI: 10.3892/ijo.2015.2978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
40 Greaves M. Return of the malingering mutants. Br J Cancer 2013;109:1391-3. [PMID: 24002605 DOI: 10.1038/bjc.2013.490] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Park SM, Hwang CY, Choi J, Joung CY, Cho KH. Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy. Oncogene 2020;39:3803-20. [PMID: 32157217 DOI: 10.1038/s41388-020-1255-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, Pace E, Harms B, Kim J, Kearns J, Fulgham A, Burenkova O, Grantcharova V, Yarar D, Paragas V, Fitzgerald J, Wainszelbaum M, West K, Mathews S, Nering R, Adiwijaya B, Garcia G, Kubasek B, Moyo V, Czibere A, Nielsen UB, MacBeath G. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121). NPJ Syst Biol Appl 2017;3:16034. [PMID: 28725482 DOI: 10.1038/npjsba.2016.34] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
43 Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517:583-588. [PMID: 25494202 DOI: 10.1038/nature14136] [Cited by in Crossref: 1458] [Cited by in F6Publishing: 1282] [Article Influence: 182.3] [Reference Citation Analysis]
44 Severyn B, Nguyen T, Altman MD, Li L, Nagashima K, Naumov GN, Sathyanarayanan S, Cook E, Morris E, Ferrer M, Arthur B, Benita Y, Watters J, Loboda A, Hermes J, Gilliland DG, Cleary MA, Carroll PM, Strack P, Tudor M, Andersen JN. Development of a High-Throughput Gene Expression Screen for Modulators of RAS-MAPK Signaling in a Mutant RAS Cellular Context. J Biomol Screen 2016;21:989-97. [PMID: 27461835 DOI: 10.1177/1087057116658646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
45 Bagrodia S, Smeal T, Abraham RT. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. Pigment Cell Melanoma Res. 2012;25:819-831. [PMID: 22883054 DOI: 10.1111/pcmr.12007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
46 Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken J, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'hoore A, Diaz-rubio E, Douillard J, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne C, Labianca R, Laurent-puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen W, Papamichael D, Pentheroudakis G, Pfeiffer P, Price T, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll H, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology 2016;27:1386-422. [DOI: 10.1093/annonc/mdw235] [Cited by in Crossref: 1387] [Cited by in F6Publishing: 1250] [Article Influence: 231.2] [Reference Citation Analysis]
47 San Lucas FA, Fowler J, Chang K, Kopetz S, Vilar E, Scheet P. Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. Mol Cancer Ther 2014;13:3230-40. [PMID: 25349306 DOI: 10.1158/1535-7163.MCT-14-0260] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
48 Hammerlindl H, Schaider H. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance. J Cell Commun Signal 2018;12:133-41. [PMID: 29192388 DOI: 10.1007/s12079-017-0435-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
49 Cho K, Clementi E, Levi-Schaffer F, Smalley KS, Radice S, Watts SW. Pharmacological research and precision cancer medicine: A call for manuscripts. Pharmacol Res 2015;102:308-9. [PMID: 26542638 DOI: 10.1016/j.phrs.2015.10.016] [Reference Citation Analysis]
50 Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 2014;513:105-9. [PMID: 25079330 DOI: 10.1038/nature13572] [Cited by in Crossref: 227] [Cited by in F6Publishing: 203] [Article Influence: 28.4] [Reference Citation Analysis]
51 Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, Runswick S, Davenport S, Heathcote K, Castro DA. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics. 2012;5:66. [PMID: 23272949 DOI: 10.1186/1755-8794-5-66] [Cited by in Crossref: 142] [Cited by in F6Publishing: 131] [Article Influence: 14.2] [Reference Citation Analysis]
52 Stenzinger A, Weichert W, Lennerz JK, Klauschen F. Basket Trials: Just the End of the First Quarter. JCO 2015;33:2823-4. [DOI: 10.1200/jco.2015.62.1516] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
53 Rafii A, Touboul C, Al Thani H, Suhre K, Malek JA. Where cancer genomics should go next: a clinician's perspective. Hum Mol Genet 2014;23:R69-75. [PMID: 24833724 DOI: 10.1093/hmg/ddu234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
54 Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282-303. [PMID: 24651011 DOI: 10.1016/j.ccr.2014.02.025] [Cited by in Crossref: 537] [Cited by in F6Publishing: 490] [Article Influence: 67.1] [Reference Citation Analysis]
55 Antonello ZA, Nucera C. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene 2014;33:5397-404. [PMID: 24362526 DOI: 10.1038/onc.2013.544] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
56 Bomane A, Gonçalves A, Ballester PJ. Paclitaxel Response Can Be Predicted With Interpretable Multi-Variate Classifiers Exploiting DNA-Methylation and miRNA Data. Front Genet 2019;10:1041. [PMID: 31708973 DOI: 10.3389/fgene.2019.01041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
57 Bajpe PK, Prahallad A, Horlings H, Nagtegaal I, Beijersbergen R, Bernards R. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene. 2015;34:531-536. [PMID: 24469059 DOI: 10.1038/onc.2013.588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
58 Wu C, Bekaii-Saab T. CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. Chemother Res Pract. 2012;2012:359041. [PMID: 22792460 DOI: 10.1155/2012/359041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.3] [Reference Citation Analysis]
59 Herrmann MD, Lennerz JK, Bullinger L, Bartholomae S, Holzmann K, Westhoff M, Corbacioglu S, Debatin K. Transitory dasatinib-resistant states in KITmut t(8;21) acute myeloid leukemia cells correlate with altered KIT expression. Experimental Hematology 2014;42:90-100. [DOI: 10.1016/j.exphem.2013.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
60 Zou J, Ji P, Zhao Y, Li L, Wei Y, Chen Y, Yang S. Neighbor communities in drug combination networks characterize synergistic effect. Mol BioSyst 2012;8:3185. [DOI: 10.1039/c2mb25267h] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
61 Charles RP, Silva J, Iezza G, Phillips WA, McMahon M. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res 2014;12:979-86. [PMID: 24770869 DOI: 10.1158/1541-7786.MCR-14-0158-T] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 7.9] [Reference Citation Analysis]
62 Voena C, Di Giacomo F, Panizza E, D'Amico L, Boccalatte FE, Pellegrino E, Todaro M, Recupero D, Tabbò F, Ambrogio C, Martinengo C, Bonello L, Pulito R, Hamm J, Chiarle R, Cheng M, Ruggeri B, Medico E, Inghirami G. The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis 2013;2:e43. [PMID: 23567620 DOI: 10.1038/oncsis.2013.7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
63 Priya SR, Dravid CS, Digumarti R, Dandekar M. Targeted Therapy for Medullary Thyroid Cancer: A Review. Front Oncol 2017;7:238. [PMID: 29057215 DOI: 10.3389/fonc.2017.00238] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
64 Brandt R, Sell T, Lüthen M, Uhlitz F, Klinger B, Riemer P, Giesecke-Thiel C, Schulze S, El-Shimy IA, Kunkel D, Fauler B, Mielke T, Mages N, Herrmann BG, Sers C, Blüthgen N, Morkel M. Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium. Nat Commun 2019;10:2919. [PMID: 31266962 DOI: 10.1038/s41467-019-10954-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
65 Ashktorab H, Azimi H, Varma S, Lee EL, Laiyemo AO, Nickerson ML, Brim H. Driver genes exome sequencing reveals distinct variants in African Americans with colorectal neoplasia. Oncotarget 2019;10:2607-24. [PMID: 31080553 DOI: 10.18632/oncotarget.26721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Sun YB, Dong JC, Xia H, Yuan XM, Jiang KT. Difference between right and left colorectal cancer. Shijie Huaren Xiaohua Zazhi 2018; 26(22): 1360-1363 [DOI: 10.11569/wcjd.v26.i22.1360] [Reference Citation Analysis]
67 Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther 2013;35:1282-303. [PMID: 24054705 DOI: 10.1016/j.clinthera.2013.08.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
68 Zhou T, Ji Y. RoBoT: a robust Bayesian hypothesis testing method for basket trials. Biostatistics 2021;22:897-912. [PMID: 32061093 DOI: 10.1093/biostatistics/kxaa005] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer 2014;120:3446-56. [PMID: 24948110 DOI: 10.1002/cncr.28864] [Cited by in Crossref: 416] [Cited by in F6Publishing: 397] [Article Influence: 52.0] [Reference Citation Analysis]
70 Gao X, Zheng F, Guo G, Liu X, Fan R, Qian ZY, Huang N, Wei YQ. Improving the anti-colon cancer activity of curcumin with biodegradable nano-micelles. J Mater Chem B 2013;1:5778-90. [PMID: 32261235 DOI: 10.1039/c3tb21091j] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
71 Ramzy GM, Koessler T, Ducrey E, McKee T, Ris F, Buchs N, Rubbia-Brandt L, Dietrich PY, Nowak-Sliwinska P. Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. Cancers (Basel) 2020;12:E1423. [PMID: 32486365 DOI: 10.3390/cancers12061423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
72 Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 2013;93:252-9. [PMID: 23361103 DOI: 10.1038/clpt.2012.237] [Cited by in Crossref: 168] [Cited by in F6Publishing: 152] [Article Influence: 16.8] [Reference Citation Analysis]
73 Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012;22:668-682. [PMID: 23153539 DOI: 10.1016/j.ccr.2012.10.009] [Cited by in Crossref: 341] [Cited by in F6Publishing: 305] [Article Influence: 37.9] [Reference Citation Analysis]
74 [DOI: 10.1101/762294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Herraiz C, Jiménez-Cervantes C, Sánchez-Laorden B, García-Borrón JC. Functional interplay between secreted ligands and receptors in melanoma. Semin Cell Dev Biol 2018;78:73-84. [PMID: 28676423 DOI: 10.1016/j.semcdb.2017.06.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
76 Brunen D, Bernards R. Drug therapy: Exploiting synthetic lethality to improve cancer therapy. Nat Rev Clin Oncol 2017;14:331-2. [PMID: 28352131 DOI: 10.1038/nrclinonc.2017.46] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
77 Kim JE, Kim KK, Kim SY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. J Cancer 2017;8:2263-8. [PMID: 28819429 DOI: 10.7150/jca.19582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
78 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
79 Arvelo F, Sojo F, Cotte C. Biology of colorectal cancer. Ecancermedicalscience 2015;9:520. [PMID: 25932044 DOI: 10.3332/ecancer.2015.520] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 7.7] [Reference Citation Analysis]
80 Cirkel GA, Gadellaa-van Hooijdonk CG, Koudijs MJ, Willems SM, Voest EE. Tumor heterogeneity and personalized cancer medicine: are we being outnumbered? Future Oncol 2014;10:417-28. [PMID: 24559448 DOI: 10.2217/fon.13.214] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
81 Huijberts SCFA, van Geel RMJM, van Brummelen EMJ, Opdam FL, Marchetti S, Steeghs N, Pulleman S, Thijssen B, Rosing H, Monkhorst K, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer. Cancer Chemother Pharmacol 2020;85:917-30. [PMID: 32274564 DOI: 10.1007/s00280-020-04066-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
82 Grassilli E, Cerrito MG, Bonomo S, Giovannoni R, Conconi D, Lavitrano M. p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors. Front Cell Dev Biol 2021;9:690365. [PMID: 34164404 DOI: 10.3389/fcell.2021.690365] [Reference Citation Analysis]
83 Fernandez ML, Dawson A, Hoenisch J, Kim H, Bamford S, Salamanca C, DiMattia G, Shepherd T, Cremona M, Hennessy B, Anderson S, Volik S, Collins CC, Huntsman DG, Carey MS. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target. Cancer Cell Int 2019;19:10. [PMID: 30636931 DOI: 10.1186/s12935-019-0725-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
84 Abdel-Maksoud MS, Ammar UM, Oh CH. Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold. Bioorg Med Chem 2019;27:2041-51. [PMID: 30955995 DOI: 10.1016/j.bmc.2019.03.062] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
85 Langan RC, Mullinax JE, Raiji MT, Upham T, Summers T, Stojadinovic A, Avital I. Colorectal cancer biomarkers and the potential role of cancer stem cells. J Cancer 2013;4:241-50. [PMID: 23459666 DOI: 10.7150/jca.5832] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.0] [Reference Citation Analysis]
86 Vakiani E. Molecular Testing of Colorectal Cancer in the Modern Era: What Are We Doing and Why? Surg Pathol Clin 2017;10:1009-20. [PMID: 29103530 DOI: 10.1016/j.path.2017.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
87 Rapakoulia T, Gao X, Huang Y, de Hoon M, Okada-Hatakeyama M, Suzuki H, Arner E. Genome-scale regression analysis reveals a linear relationship for promoters and enhancers after combinatorial drug treatment. Bioinformatics 2017;33:3696-700. [PMID: 28961713 DOI: 10.1093/bioinformatics/btx503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
88 Won JK, Yang HW, Shin SY, Lee JH, Heo WD, Cho KH. The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor. J Mol Cell Biol. 2012;4:153-163. [PMID: 22561840 DOI: 10.1093/jmcb/mjs021] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
89 Ban MJ, Byeon HK, Yang YJ, An S, Kim JW, Kim JH, Kim DH, Yang J, Kee H, Koh YW. Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition. Cancer Sci 2018;109:3816-25. [PMID: 30343534 DOI: 10.1111/cas.13839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
90 Zou ZZ, Nie PP, Li YW, Hou BX, Rui-Li, Shi XP, Ma ZK, Han BW, Luo XY. Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. Oncotarget 2017;8:22414-32. [PMID: 26461472 DOI: 10.18632/oncotarget.5628] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
91 Kummar S, Doroshow JH. Molecular targets in cancer therapy. Expert Review of Anticancer Therapy 2014;13:267-9. [DOI: 10.1586/era.12.170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
92 Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26:207-221. [PMID: 25065853 DOI: 10.1016/j.ccr.2014.05.019] [Cited by in Crossref: 330] [Cited by in F6Publishing: 323] [Article Influence: 41.3] [Reference Citation Analysis]
93 Huijberts SCFA, Boelens MC, Bernards R, Opdam FL. Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. Br J Cancer 2021;124:176-82. [PMID: 33204026 DOI: 10.1038/s41416-020-01147-2] [Reference Citation Analysis]
94 Rahman M, Salajegheh A, Smith R, Lam A. BRAF inhibitors: From the laboratory to clinical trials. Critical Reviews in Oncology/Hematology 2014;90:220-32. [DOI: 10.1016/j.critrevonc.2013.12.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
95 Obaid NM, Bedard K, Huang WY. Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations. Int J Mol Sci 2017;18:E585. [PMID: 28282860 DOI: 10.3390/ijms18030585] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
96 Battaglin F, Dadduzio V, Bergamo F, Manai C, Schirripa M, Lonardi S, Zagonel V, Loupakis F. Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. Expert Opin Biol Ther 2017;17:1297-308. [PMID: 28752777 DOI: 10.1080/14712598.2017.1356815] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
97 Wang CY, Guo ST, Wang JY, Yan XG, Farrelly M, Zhang YY, Liu F, Yari H, La T, Lei FX, Jin L, Zhang XD, Jiang CC. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922. Oncotarget 2016;7:49597-610. [PMID: 27391062 DOI: 10.18632/oncotarget.10414] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
98 Errington TM, Denis A, Perfito N, Iorns E, Nosek BA. Challenges for assessing replicability in preclinical cancer biology. Elife 2021;10:e67995. [PMID: 34874008 DOI: 10.7554/eLife.67995] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
99 Ahn DH, Goldberg RM. Colorectal clinical trials: what is on the horizon? Future Oncol 2016;12:525-31. [PMID: 26777152 DOI: 10.2217/fon.15.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
100 Yaeger R, Yao Z, Hyman DM, Hechtman JF, Vakiani E, Zhao H, Su W, Wang L, Joelson A, Cercek A, Baselga J, de Stanchina E, Saltz L, Berger MF, Solit DB, Rosen N. Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Res 2017;77:6513-23. [PMID: 28951457 DOI: 10.1158/0008-5472.CAN-17-0768] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 6.6] [Reference Citation Analysis]
101 Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016; 22(28): 6345-6361 [PMID: 27605871 DOI: 10.3748/wjg.v22.i28.6345] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
102 Caruso S, Calatayud A, Pilet J, La Bella T, Rekik S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-udilova N, Péneau C, Grasl-kraupp B, de Koning L, Ouine B, Bioulac-sage P, Couchy G, Calderaro J, Nault J, Zucman-rossi J, Rebouissou S. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology 2019;157:760-76. [DOI: 10.1053/j.gastro.2019.05.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 15.3] [Reference Citation Analysis]
103 Prahallad A, Heynen GJ, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Bernards R. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell Rep 2015;12:1978-85. [PMID: 26365186 DOI: 10.1016/j.celrep.2015.08.037] [Cited by in Crossref: 100] [Cited by in F6Publishing: 85] [Article Influence: 14.3] [Reference Citation Analysis]
104 Kholodenko BN, Rauch N, Kolch W, Rukhlenko OS. A systematic analysis of signaling reactivation and drug resistance. Cell Rep 2021;35:109157. [PMID: 34038718 DOI: 10.1016/j.celrep.2021.109157] [Reference Citation Analysis]
105 Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. J Thorac Oncol 2019;14:802-15. [PMID: 30831205 DOI: 10.1016/j.jtho.2018.12.038] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
106 Wahjudi LW, Bernhardt S, Abnaof K, Horak P, Kreutzfeldt S, Heining C, Borgoni S, Becki C, Berg D, Richter D, Hutter B, Uhrig S, Pfütze K, Leichsenring J, Glimm H, Brors B, von Kalle C, Stenzinger A, Korf U, Fröhling S, Wiemann S. Integrating proteomics into precision oncology. Int J Cancer 2021;148:1438-51. [PMID: 32949162 DOI: 10.1002/ijc.33301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
107 van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov. 2017;7:610-619. [PMID: 28363909 DOI: 10.1158/2159-8290.cd-16-0795] [Cited by in Crossref: 101] [Cited by in F6Publishing: 60] [Article Influence: 20.2] [Reference Citation Analysis]
108 Heynen GJ, Fonfara A, Bernards R. Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle 2014;13:3808-17. [PMID: 25426675 DOI: 10.4161/15384101.2014.988033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
109 Orlandi A, Calegari A, Inno A, Berenato R, Caporale M, Niger M, Bossi I, Di Bartolomeo M, de Braud F, Pietrantonio F. BRAF in metastatic colorectal cancer: the future starts now. Pharmacogenomics 2015;16:2069-81. [PMID: 26615988 DOI: 10.2217/pgs.15.140] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
110 Sinicrope FA. Evaluating the Combination of Microsatellite Instability and Mutation in BRAF as Prognostic Factors for Patients With Colorectal Cancer. Clin Gastroenterol Hepatol 2019;17:391-4. [PMID: 29966708 DOI: 10.1016/j.cgh.2018.06.038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
111 Li Q, Zhang D, Chen X, He L, Li T, Xu X, Li M. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Sci Rep 2015;5:16082. [PMID: 26542452 DOI: 10.1038/srep16082] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 7.7] [Reference Citation Analysis]
112 Unger K. Integrative radiation systems biology. Radiat Oncol 2014;9:21. [PMID: 24411063 DOI: 10.1186/1748-717X-9-21] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
113 Nakagomi N, Sakamoto D, Hirose T, Takagi T, Murase M, Nakagomi T, Yoshimura S, Hirota S. Epithelioid glioblastoma with microglia features: potential for novel therapy. Brain Pathol 2020;30:1119-33. [PMID: 32687679 DOI: 10.1111/bpa.12887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Wang W, Kandimalla R, Huang H, Zhu L, Li Y, Gao F, Goel A, Wang X. Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities. Semin Cancer Biol. 2019;55:37-52. [PMID: 29775690 DOI: 10.1016/j.semcancer.2018.05.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
115 Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112:1888-1894. [PMID: 25989278 DOI: 10.1038/bjc.2015.173] [Cited by in Crossref: 188] [Cited by in F6Publishing: 168] [Article Influence: 26.9] [Reference Citation Analysis]
116 De Conti G, Dias MH, Bernards R. Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells. Cancers (Basel) 2021;13:1118. [PMID: 33807785 DOI: 10.3390/cancers13051118] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. PLoS One 2015;10:e0138210. [PMID: 26405815 DOI: 10.1371/journal.pone.0138210] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
118 Kloth M, Buettner R. Changing histopathological diagnostics by genome-based tumor classification. Genes (Basel) 2014;5:444-59. [PMID: 24879454 DOI: 10.3390/genes5020444] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
119 Maiello MR, D'alessio A, Bevilacqua S, Gallo M, Normanno N, De Luca A. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells: E GFR A ND M EK B LOCKADE I n T RIPLE N EGATIVE B REAST. J Cell Biochem 2015;116:2778-85. [DOI: 10.1002/jcb.25220] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
120 Dyer MJS, Vogler M, Samuel J, Jayne S, Wagner S, Pritchard C, Macip S. Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls. Br J Haematol 2013;160:725-33. [DOI: 10.1111/bjh.12219] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
121 Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, Lin R, He WL, Cai SR, He YL, Ye JN. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep (Oxf) 2020;8:179-91. [PMID: 32665850 DOI: 10.1093/gastro/goaa026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
122 Méhes G, Irsai G, Bedekovics J, Beke L, Fazakas F, Rózsa T, Kiss C. Activating BRAF V600E Mutation in Aggressive Pediatric Langerhans Cell Histiocytosis: Demonstration by Allele-specific PCR/Direct Sequencing and Immunohistochemistry. American Journal of Surgical Pathology 2014;38:1644-8. [DOI: 10.1097/pas.0000000000000304] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
123 Moujaber T, Etemadmoghadam D, Kennedy CJ, Chiew Y, Balleine RL, Saunders C, Wain GV, Gao B, Hogg R, Srirangan S, Kan C, Fereday S, Traficante N, Patch A, Pearson JV, Waddell N, Grimmond SM, Dobrovic A, Bowtell DD, Harnett PR, deFazio A; Australian Ovarian Cancer Study. BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00221] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
124 Akkad J, Bochum S, Martens UM. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. Langenbecks Arch Surg 2015;400:129-43. [DOI: 10.1007/s00423-015-1276-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
125 Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep 2014;7:1940-55. [PMID: 24931611 DOI: 10.1016/j.celrep.2014.05.032] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
126 Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what's next after PARP inhibitors? Nat Rev Clin Oncol 2018;15:564-76. [PMID: 29955114 DOI: 10.1038/s41571-018-0055-6] [Cited by in Crossref: 155] [Cited by in F6Publishing: 135] [Article Influence: 51.7] [Reference Citation Analysis]
127 Shen J, Li L, Yang T, Cohen PS, Sun G. Biphasic Mathematical Model of Cell-Drug Interaction That Separates Target-Specific and Off-Target Inhibition and Suggests Potent Targeted Drug Combinations for Multi-Driver Colorectal Cancer Cells. Cancers (Basel) 2020;12:E436. [PMID: 32069833 DOI: 10.3390/cancers12020436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
128 Cao Y, Chong Y, Shen H, Zhang M, Huang J, Zhu Y, Zhang Z. Combination of TNF-α and graphene oxide-loaded BEZ235 to enhance apoptosis of PIK3CA mutant colorectal cancer cells. J Mater Chem B 2013;1:5602. [DOI: 10.1039/c3tb20764a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
129 Bhattarai PY, Kim G, Poudel M, Lim SC, Choi HS. METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation. Cancer Lett 2021;522:44-56. [PMID: 34530048 DOI: 10.1016/j.canlet.2021.09.015] [Reference Citation Analysis]
130 Sanson KR, Hanna RE, Hegde M, Donovan KF, Strand C, Sullender ME, Vaimberg EW, Goodale A, Root DE, Piccioni F, Doench JG. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun 2018;9:5416. [PMID: 30575746 DOI: 10.1038/s41467-018-07901-8] [Cited by in Crossref: 183] [Cited by in F6Publishing: 140] [Article Influence: 45.8] [Reference Citation Analysis]
131 Murphy P, Glynn D, Dias S, Hodgson R, Claxton L, Beresford L, Cooper K, Tappenden P, Ennis K, Grosso A, Wright K, Cantrell A, Stevenson M, Palmer S. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health Technol Assess 2021;25:1-228. [PMID: 34990339 DOI: 10.3310/hta25760] [Reference Citation Analysis]
132 Hatanaka M, Higashi Y, Kawai K, Su J, Zeng W, Chen X, Kanekura T. CD147-targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation. Oncol Lett 2016;11:2424-8. [PMID: 27073491 DOI: 10.3892/ol.2016.4267] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
133 Martini G, Ciardiello D, Vitiello PP, Napolitano S, Cardone C, Cuomo A, Troiani T, Ciardiello F, Martinelli E. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? Cancer Treat Rev 2020;86:102023. [PMID: 32474402 DOI: 10.1016/j.ctrv.2020.102023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
134 Goulielmaki M, Assimomytis N, Rozanc J, Taki E, Christodoulou I, Alexopoulos LG, Zoumpourlis V, Pintzas A, Papahatjis D. DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties. Transl Oncol 2019;12:932-50. [PMID: 31096110 DOI: 10.1016/j.tranon.2019.04.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
135 Sato M. Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer. Oncol Lett 2020;19:3617-26. [PMID: 32391087 DOI: 10.3892/ol.2020.11512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 De S, Ganesan S. Looking beyond drivers and passengers in cancer genome sequencing data. Ann Oncol 2017;28:938-45. [PMID: 27998972 DOI: 10.1093/annonc/mdw677] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
137 Kanat O, Ertas H, Caner B. Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations. World J Gastrointest Oncol 2020; 12(10): 1080-1090 [PMID: 33133378 DOI: 10.4251/wjgo.v12.i10.1080] [Reference Citation Analysis]
138 Cabanos HF, Hata AN. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers (Basel) 2021;13:2666. [PMID: 34071428 DOI: 10.3390/cancers13112666] [Reference Citation Analysis]
139 Prasetyanti PR, Capone E, Barcaroli D, D'Agostino D, Volpe S, Benfante A, van Hooff S, Iacobelli V, Rossi C, Iacobelli S, Medema JP, De Laurenzi V, Sala G. ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). Oncotarget 2015;6:16902-11. [PMID: 26160848 DOI: 10.18632/oncotarget.4642] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
140 Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;14:455-67. [PMID: 24957944 DOI: 10.1038/nrc3760] [Cited by in Crossref: 456] [Cited by in F6Publishing: 407] [Article Influence: 57.0] [Reference Citation Analysis]
141 Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13:140-156. [PMID: 24481312 DOI: 10.1038/nrd4204] [Cited by in Crossref: 1026] [Cited by in F6Publishing: 954] [Article Influence: 128.3] [Reference Citation Analysis]
142 Smith MP, Wellbrock C. Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance. Clin Cancer Res 2016;22:5966-70. [PMID: 27797970 DOI: 10.1158/1078-0432.CCR-16-0954] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
143 Pai SG, Fuloria J. Novel therapeutic agents in the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(1): 99-104 [PMID: 26798440 DOI: 10.4251/wjgo.v8.i1.99] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
144 Palve V, Liao Y, Remsing Rix LL, Rix U. Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Semin Cancer Biol 2021;68:209-29. [PMID: 32044472 DOI: 10.1016/j.semcancer.2020.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
145 Abdel-Rahman O. Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside. Future Oncol 2016;12:25-30. [PMID: 26616508 DOI: 10.2217/fon.15.226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
146 Kim HS, Sung YJ, Paik S. Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine. Yonsei Med J 2015;56:1186-98. [PMID: 26256959 DOI: 10.3349/ymj.2015.56.5.1186] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
147 Bidshahri R, Attali D, Fakhfakh K, McNeil K, Karsan A, Won JR, Wolber R, Bryan J, Hughesman C, Haynes C. Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay. J Mol Diagn 2016;18:190-204. [PMID: 26762843 DOI: 10.1016/j.jmoldx.2015.09.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
148 Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. Mol Oncol 2017;11:1263-72. [PMID: 28618197 DOI: 10.1002/1878-0261.12099] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
149 Haselgrübler T, Haider M, Ji B, Juhasz K, Sonnleitner A, Balogi Z, Hesse J. High-throughput, multiparameter analysis of single cells. Anal Bioanal Chem 2014;406:3279-96. [PMID: 24292433 DOI: 10.1007/s00216-013-7485-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
150 Cohen R, Cervera P, Svrcek M, Pellat A, Dreyer C, de Gramont A, André T. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? Curr Treat Options Oncol 2017;18:9. [PMID: 28214977 DOI: 10.1007/s11864-017-0453-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
151 Halle BR, Johnson DB. Defining and Targeting BRAF Mutations in Solid Tumors. Curr Treat Options Oncol 2021;22:30. [PMID: 33641072 DOI: 10.1007/s11864-021-00827-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
152 Jiang L, Chu H, Zheng H. B-Raf mutation and papillary thyroid carcinoma patients. Oncol Lett 2016;11:2699-705. [PMID: 27073540 DOI: 10.3892/ol.2016.4298] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
153 Toon CW, Chou A, DeSilva K, Chan J, Patterson J, Clarkson A, Sioson L, Jankova L, Gill AJ. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod Pathol. 2014;27:644-650. [PMID: 24157612 DOI: 10.1038/modpathol.2013.200] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
154 Russo M, Crisafulli G, Sogari A, Reilly NM, Arena S, Lamba S, Bartolini A, Amodio V, Magrì A, Novara L, Sarotto I, Nagel ZD, Piett CG, Amatu A, Sartore-Bianchi A, Siena S, Bertotti A, Trusolino L, Corigliano M, Gherardi M, Lagomarsino MC, Di Nicolantonio F, Bardelli A. Adaptive mutability of colorectal cancers in response to targeted therapies. Science 2019;366:1473-80. [PMID: 31699882 DOI: 10.1126/science.aav4474] [Cited by in Crossref: 107] [Cited by in F6Publishing: 99] [Article Influence: 35.7] [Reference Citation Analysis]
155 Bahrami A, Hesari A, Khazaei M, Hassanian SM, Ferns GA, Avan A. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. J Cell Physiol 2018;233:2162-9. [DOI: 10.1002/jcp.25952] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
156 Tripathy D, Harnden K, Blackwell K, Robson M. Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic? BMC Med 2014;12:140. [PMID: 25286031 DOI: 10.1186/s12916-014-0140-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
157 Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014;5:2997. [PMID: 24429703 DOI: 10.1038/ncomms3997] [Cited by in Crossref: 524] [Cited by in F6Publishing: 492] [Article Influence: 74.9] [Reference Citation Analysis]
158 Tokheim C, Karchin R. CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers. Cell Syst 2019;9:9-23.e8. [PMID: 31202631 DOI: 10.1016/j.cels.2019.05.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 14.3] [Reference Citation Analysis]
159 Lou YF, Zou ZZ, Chen PJ, Huang GB, Li B, Zheng DQ, Yu XR, Luo XY. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PLoS One 2014;9:e97719. [PMID: 24874286 DOI: 10.1371/journal.pone.0097719] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
160 Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH, Cheng HW, Li YQ, Ambudkar SV, Hsu SC. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem Pharmacol 2013;85:325-34. [PMID: 23153455 DOI: 10.1016/j.bcp.2012.11.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
161 Nappi A, Nasti G, Romano C, Berretta M, Ottaiano A. Metastatic Colorectal Cancer: Prognostic and Predictive Factors. Curr Med Chem 2020;27:2779-91. [PMID: 31218949 DOI: 10.2174/0929867326666190620110732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Wang K, Li Y, Song N, Che X, Hou K, Xu L, Bai M, Wang Q, Wang Y, Zhou Y, Cao M, Liu Y, Zhang J. Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAFV600E mutation. J Cell Biochem 2019;120:5315-25. [PMID: 30320916 DOI: 10.1002/jcb.27808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
163 Ibarrola-Villava M, Cervantes A, Bardelli A. Preclinical models for precision oncology. Biochim Biophys Acta Rev Cancer 2018;1870:239-46. [PMID: 29959990 DOI: 10.1016/j.bbcan.2018.06.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
164 Valdeira ASC, Ritt DA, Morrison DK, McMahon JB, Gustafson KR, Salvador JAR. Synthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade Signaling. Front Chem 2018;6:434. [PMID: 30324102 DOI: 10.3389/fchem.2018.00434] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
165 Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol 2021;39:285-94. [PMID: 33356422 DOI: 10.1200/JCO.20.01994] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
166 Albano G, Giorno V, Román-román P, Román-román S, Torres-ruiz F. Estimating and determining the effect of a therapy on tumor dynamics by means of a modified Gompertz diffusion process. Journal of Theoretical Biology 2015;364:206-19. [DOI: 10.1016/j.jtbi.2014.09.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
167 Inaba K, Oda K, Aoki K, Sone K, Ikeda Y, Miyasaka A, Kashiyama T, Fukuda T, Makii C, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T. Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging. Oncotarget 2016;7:29577-91. [PMID: 27102436 DOI: 10.18632/oncotarget.8807] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
168 Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, Hon CS, Munoz B, Bittker JA, Stockwell BR, Khabele D, Stern AM, Clemons PA, Shamji AF, Schreiber SL. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 2013;154:1151-61. [PMID: 23993102 DOI: 10.1016/j.cell.2013.08.003] [Cited by in Crossref: 366] [Cited by in F6Publishing: 291] [Article Influence: 40.7] [Reference Citation Analysis]
169 Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patanè DA, Pani A, Scaglione F, Siena S, Sartore-Bianchi A. Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open 2021;6:100156. [PMID: 34044286 DOI: 10.1016/j.esmoop.2021.100156] [Reference Citation Analysis]
170 Peron M, Lovisa F, Poli E, Basso G, Bonvini P. Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors. PLoS One 2015;10:e0132330. [PMID: 26147305 DOI: 10.1371/journal.pone.0132330] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
171 Rosell R, Karachaliou N, Morales-Espinosa D, Costa C, Molina MA, Sansano I, Gasco A, Viteri S, Massuti B, Wei J, González Cao M, Martínez Bueno A. Adaptive resistance to targeted therapies in cancer. Transl Lung Cancer Res 2013;2:152-9. [PMID: 25806228 DOI: 10.3978/j.issn.2218-6751.2012.12.08] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
172 Ahmed TA, Adamopoulos C, Karoulia Z, Wu X, Sachidanandam R, Aaronson SA, Poulikakos PI. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. Cell Rep 2019;26:65-78.e5. [PMID: 30605687 DOI: 10.1016/j.celrep.2018.12.013] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 29.5] [Reference Citation Analysis]
173 Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di nicolantonio F, Bardelli A. RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells. Cell Reports 2014;8:1475-83. [DOI: 10.1016/j.celrep.2014.07.033] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 10.4] [Reference Citation Analysis]
174 Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C, Sharma J. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. J Surg Res 2013;185:217-24. [PMID: 23746767 DOI: 10.1016/j.jss.2013.05.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
175 Yang G, Yan Y, Ma Y, Yang Y. Vitamin C at high concentrations induces cytotoxicity in malignant melanoma but promotes tumor growth at low concentrations. Mol Carcinog 2017;56:1965-76. [PMID: 28370562 DOI: 10.1002/mc.22654] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
176 Couto M, García MF, Alamón C, Cabrera M, Cabral P, Merlino A, Teixidor F, Cerecetto H, Viñas C. Discovery of Potent EGFR Inhibitors through the Incorporation of a 3D-Aromatic-Boron-Rich-Cluster into the 4-Anilinoquinazoline Scaffold: Potential Drugs for Glioma Treatment. Chemistry 2018;24:3122-6. [PMID: 29194843 DOI: 10.1002/chem.201705181] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
177 Baur F, Nietzer SL, Kunz M, Saal F, Jeromin J, Matschos S, Linnebacher M, Walles H, Dandekar T, Dandekar G. Connecting Cancer Pathways to Tumor Engines: A Stratification Tool for Colorectal Cancer Combining Human In Vitro Tissue Models with Boolean In Silico Models. Cancers (Basel) 2019;12:E28. [PMID: 31861874 DOI: 10.3390/cancers12010028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
178 Tosi D, Pérez-Gracia E, Atis S, Vié N, Combès E, Gabanou M, Larbouret C, Jarlier M, Mollevi C, Torro A, Del Rio M, Martineau P, Gongora C. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. BMC Cancer 2018;18:812. [PMID: 30103709 DOI: 10.1186/s12885-018-4712-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
179 Klinghammer K, Walther W, Hoffmann J. Choosing wisely - Preclinical test models in the era of precision medicine. Cancer Treat Rev 2017;55:36-45. [PMID: 28314175 DOI: 10.1016/j.ctrv.2017.02.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
180 Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 2013;3:52-67. [PMID: 23239741 DOI: 10.1158/2159-8290.CD-12-0408] [Cited by in Crossref: 82] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
181 Carson R, Celtikci B, Fenning C, Javadi A, Crawford N, Carbonell LP, Lawler M, Longley DB, Johnston PG, Van Schaeybroeck S. HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL. Clin Cancer Res 2015;21:3230-40. [PMID: 25813020 DOI: 10.1158/1078-0432.CCR-14-2701] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
182 Matos P, Gonçalves V, Jordan P. Targeting the serrated pathway of colorectal cancer with mutation in BRAF. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2016;1866:51-63. [DOI: 10.1016/j.bbcan.2016.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
183 Lodhia KA, Hadley AM, Haluska P, Scott CL. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta 2015;1855:223-34. [PMID: 25783201 DOI: 10.1016/j.bbcan.2015.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
184 Adamopoulos C, Ahmed TA, Tucker MR, Ung PMU, Xiao M, Karoulia Z, Amabile A, Wu X, Aaronson SA, Ang C, Rebecca VW, Brown BD, Schlessinger A, Herlyn M, Wang Q, Shaw DE, Poulikakos PI. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discov 2021;11:1716-35. [PMID: 33568355 DOI: 10.1158/2159-8290.CD-20-1351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
185 Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov 2018;8:428-43. [PMID: 29431699 DOI: 10.1158/2159-8290.CD-17-1226] [Cited by in Crossref: 235] [Cited by in F6Publishing: 135] [Article Influence: 58.8] [Reference Citation Analysis]
186 Groenendijk FH, Bernards R. Drug resistance to targeted therapies: déjà vu all over again. Mol Oncol. 2014;8:1067-1083. [PMID: 24910388 DOI: 10.1016/j.molonc.2014.05.004] [Cited by in Crossref: 131] [Cited by in F6Publishing: 112] [Article Influence: 16.4] [Reference Citation Analysis]
187 Koplev S, Longden J, Ferkinghoff-borg J, Blicher Bjerregård M, Cox TR, Erler JT, Pedersen JT, Voellmy F, Sommer MO, Linding R. Dynamic Rearrangement of Cell States Detected by Systematic Screening of Sequential Anticancer Treatments. Cell Reports 2017;20:2784-91. [DOI: 10.1016/j.celrep.2017.08.095] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
188 Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A. Exploring the best treatment options for BRAF-mutant metastatic colon cancer. Br J Cancer 2019;121:434-42. [PMID: 31353365 DOI: 10.1038/s41416-019-0526-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
189 Tan J, Liu R, Zhu G, Umbricht CB, Xing M. TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel. Proc Natl Acad Sci U S A 2020;117:15846-51. [PMID: 32561648 DOI: 10.1073/pnas.2004707117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
190 McCoach CE, Doebele RC. The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol 2014;15:644-57. [PMID: 25228144 DOI: 10.1007/s11864-014-0310-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
191 Barras D. BRAF Mutation in Colorectal Cancer: An Update. Biomark Cancer. 2015;7:9-12. [PMID: 26396549 DOI: 10.4137/bic.s25248] [Cited by in Crossref: 35] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
192 Kim JW, Abudayyeh OO, Yeerna H, Yeang CH, Stewart M, Jenkins RW, Kitajima S, Konieczkowski DJ, Medetgul-Ernar K, Cavazos T, Mah C, Ting S, Van Allen EM, Cohen O, Mcdermott J, Damato E, Aguirre AJ, Liang J, Liberzon A, Alexe G, Doench J, Ghandi M, Vazquez F, Weir BA, Tsherniak A, Subramanian A, Meneses-Cime K, Park J, Clemons P, Garraway LA, Thomas D, Boehm JS, Barbie DA, Hahn WC, Mesirov JP, Tamayo P. Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Syst 2017;5:105-118.e9. [PMID: 28837809 DOI: 10.1016/j.cels.2017.08.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
193 Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 2012;17:205-16. [PMID: 22865098 DOI: 10.1007/s10911-012-9264-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
194 Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P, Adamson PC. New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol. 2013;14:e117-e124. [PMID: 23434337 DOI: 10.1016/s1470-2045(13)70013-5] [Cited by in Crossref: 67] [Cited by in F6Publishing: 20] [Article Influence: 7.4] [Reference Citation Analysis]
195 Jiménez-Mora E, Gallego B, Díaz-Gago S, Lasa M, Baquero P, Chiloeches A. V600EBRAF Inhibition Induces Cytoprotective Autophagy through AMPK in Thyroid Cancer Cells. Int J Mol Sci 2021;22:6033. [PMID: 34204950 DOI: 10.3390/ijms22116033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 DeVita VT Jr, Eggermont AM, Hellman S, Kerr DJ. Clinical cancer research: the past, present and the future. Nat Rev Clin Oncol 2014;11:663-9. [PMID: 25245981 DOI: 10.1038/nrclinonc.2014.153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
197 Ali EMH, Abdel-Maksoud MS, Ammar UM, Mersal KI, Ho Yoo K, Jooryeong P, Oh CH. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600Einhibitors. Bioorg Chem 2021;106:104508. [PMID: 33280830 DOI: 10.1016/j.bioorg.2020.104508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
198 Weigelt B, Downward J. Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. Front Oncol 2012;2:109. [PMID: 22970424 DOI: 10.3389/fonc.2012.00109] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
199 Bon G, Loria R, Amoreo CA, Verdina A, Sperduti I, Mastrofrancesco A, Soddu S, Diodoro MG, Mottolese M, Todaro M, Stassi G, Milella M, De Maria R, Falcioni R. Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Oncotarget 2017;8:108463-79. [PMID: 29312543 DOI: 10.18632/oncotarget.11400] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
200 Johnson J, Thijssen B, McDermott U, Garnett M, Wessels LF, Bernards R. Targeting the RB-E2F pathway in breast cancer. Oncogene. 2016;35:4829-4835. [PMID: 26923330 DOI: 10.1038/onc.2016.32] [Cited by in Crossref: 104] [Cited by in F6Publishing: 99] [Article Influence: 17.3] [Reference Citation Analysis]
201 Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, Ajani JA. Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol 2017;13:919-34. [PMID: 28067073 DOI: 10.2217/fon-2016-0422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
202 Klauschen F. Mutationsprofile von Tumoren jenseits von Organ- und Gewebespezifität: Implikationen für Diagnostik und klinisches Studiendesign. Pathologe 2014;35:277-80. [DOI: 10.1007/s00292-014-2027-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
203 Colic M, Wang G, Zimmermann M, Mascall K, McLaughlin M, Bertolet L, Lenoir WF, Moffat J, Angers S, Durocher D, Hart T. Identifying chemogenetic interactions from CRISPR screens with drugZ. Genome Med 2019;11:52. [PMID: 31439014 DOI: 10.1186/s13073-019-0665-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
204 Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology. 2016;150:48-63. [PMID: 26385075 DOI: 10.1053/j.gastro.2015.08.056] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 9.0] [Reference Citation Analysis]
205 Gong J, Cho M, Fakih M. RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol 2016;7:687-704. [PMID: 27747083 DOI: 10.21037/jgo.2016.06.12] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
206 Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, de Man J, Tanizawa Y, Kawase Y, Yoshino K, Buijsman RC, Zaman GJ. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One 2014;9:e92146. [PMID: 24651269 DOI: 10.1371/journal.pone.0092146] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
207 Kamata T, Dankort D, Kang J, Giblett S, Pritchard CA, McMahon M, Leavitt AD. Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res 2013;11:1530-41. [PMID: 24152792 DOI: 10.1158/1541-7786.MCR-13-0294] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
208 Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P, Sieber O, Waring P, Desai J. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol 2015;10:99-109. [PMID: 24859797 DOI: 10.1007/s11523-014-0319-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
209 Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 2015;47:250-6. [PMID: 25665005 DOI: 10.1038/ng.3218] [Cited by in Crossref: 277] [Cited by in F6Publishing: 260] [Article Influence: 39.6] [Reference Citation Analysis]
210 Ghosh S, Varela L, Sood A, Park BH, Lotan TL. mTOR signaling feedback modulates mammary epithelial differentiation and restrains invasion downstream of PTEN loss. Cancer Res 2013;73:5218-31. [PMID: 23774212 DOI: 10.1158/0008-5472.CAN-13-0429] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
211 Wang J, Li R, Li J, Yi Y, Liu X, Chen J, Zhang H, Lu J, Li C, Wu H, Liang Z. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing. J Transl Med 2021;19:433. [PMID: 34657620 DOI: 10.1186/s12967-021-03108-6] [Reference Citation Analysis]
212 Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN. Synthetic Lethality in Cancer Therapeutics: The Next Generation. Cancer Discov 2021;11:1626-35. [PMID: 33795234 DOI: 10.1158/2159-8290.CD-20-1503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
213 Yu IS, Cheung WY. Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy. Can J Gastroenterol Hepatol 2018;2018:9450754. [PMID: 30519549 DOI: 10.1155/2018/9450754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
214 Hayes DN, Kim WY. The next steps in next-gen sequencing of cancer genomes. J Clin Invest 2015;125:462-8. [PMID: 25642706 DOI: 10.1172/JCI68339] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
215 Aleksakhina SN, Imyanitov EN. Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. Int J Mol Sci 2021;22:10931. [PMID: 34681592 DOI: 10.3390/ijms222010931] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Tamas K, Walenkamp AM, de Vries EG, van Vugt MA, Beets-Tan RG, van Etten B, de Groot DJ, Hospers GA. Rectal and colon cancer: Not just a different anatomic site. Cancer Treat Rev. 2015;41:671-679. [PMID: 26145760 DOI: 10.1016/j.ctrv.2015.06.007] [Cited by in Crossref: 131] [Cited by in F6Publishing: 129] [Article Influence: 18.7] [Reference Citation Analysis]
217 Jin Z, Sinicrope FA. Advances in the therapy of BRAFV600E metastatic colorectal cancer. Expert Rev Anticancer Ther 2019;19:823-9. [PMID: 31455117 DOI: 10.1080/14737140.2019.1661778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
218 Neuzillet C, Rousseau B, Kocher H, Bourget P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. Pharmacol Ther. 2017;174:145-172. [PMID: 28223233 DOI: 10.1016/j.pharmthera.2017.02.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
219 Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. Cancer Treat Rev 2013;39:592-601. [PMID: 23375249 DOI: 10.1016/j.ctrv.2012.12.011] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 9.4] [Reference Citation Analysis]
220 Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 2016;375:1054-1067. [PMID: 27626519 DOI: 10.1056/nejmra1501993] [Cited by in Crossref: 299] [Cited by in F6Publishing: 165] [Article Influence: 49.8] [Reference Citation Analysis]
221 Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid 2020;30:1288-96. [PMID: 32216548 DOI: 10.1089/thy.2019.0514] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
222 Syn NL, Yong WP, Goh BC, Lee SC. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. Expert Opin Drug Metab Toxicol 2016;12:911-22. [PMID: 27249175 DOI: 10.1080/17425255.2016.1196187] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
223 Andre F, Mardis E, Salm M, Soria JC, Siu LL, Swanton C. Prioritizing targets for precision cancer medicine. Ann Oncol. 2014;25:2295-2303. [PMID: 25344359 DOI: 10.1093/annonc/mdu478] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 11.8] [Reference Citation Analysis]
224 Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A, Turner NC. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov 2013;3:1058-71. [PMID: 23744832 DOI: 10.1158/2159-8290.CD-12-0569] [Cited by in Crossref: 79] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
225 Matsuoka T, Yashiro M. Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. World J Gastrointest Oncol 2021; 13(5): 366-390 [PMID: 34040699 DOI: 10.4251/wjgo.v13.i5.366] [Reference Citation Analysis]
226 Haigis KM, Cichowski K, Elledge SJ. Tissue-specificity in cancer: The rule, not the exception. Science 2019;363:1150-1. [PMID: 30872507 DOI: 10.1126/science.aaw3472] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 21.7] [Reference Citation Analysis]
227 Manchado E, Weissmueller S, Morris JP 4th, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 2016;534:647-51. [PMID: 27338794 DOI: 10.1038/nature18600] [Cited by in Crossref: 216] [Cited by in F6Publishing: 203] [Article Influence: 36.0] [Reference Citation Analysis]
228 Ruess DA, Heynen GJ, Ciecielski KJ, Ai J, Berninger A, Kabacaoglu D, Görgülü K, Dantes Z, Wörmann SM, Diakopoulos KN, Karpathaki AF, Kowalska M, Kaya-aksoy E, Song L, van der Laan EAZ, López-alberca MP, Nazaré M, Reichert M, Saur D, Erkan MM, Hopt UT, Sainz B, Birchmeier W, Schmid RM, Lesina M, Algül H. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Nat Med 2018;24:954-60. [DOI: 10.1038/s41591-018-0024-8] [Cited by in Crossref: 140] [Cited by in F6Publishing: 127] [Article Influence: 35.0] [Reference Citation Analysis]
229 Asmussen J, Lasater EA, Tajon C, Oses-Prieto J, Jun YW, Taylor BS, Burlingame A, Craik CS, Shah NP. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer Discov 2014;4:200-15. [PMID: 24362263 DOI: 10.1158/2159-8290.CD-13-0235] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
230 Johnson B, Jin Z, Truty MJ, Smoot RL, Nagorney DM, Kendrick ML, Kipp BR, Grothey A. Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist 2018;23:128-34. [PMID: 28904173 DOI: 10.1634/theoncologist.2017-0230] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
231 Mauri G, Bonazzina E, Amatu A, Tosi F, Bencardino K, Gori V, Massihnia D, Cipani T, Spina F, Ghezzi S, Siena S, Sartore-Bianchi A. The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:E137. [PMID: 33406649 DOI: 10.3390/cancers13010137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
232 Nijman SM, Friend SH. Cancer. Potential of the synthetic lethality principle. Science 2013;342:809-11. [PMID: 24233712 DOI: 10.1126/science.1244669] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
233 Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Rep 2020;32:107994. [PMID: 32755586 DOI: 10.1016/j.celrep.2020.107994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Collisson EA, Cho RJ, Gray JW. What are we learning from the cancer genome? Nat Rev Clin Oncol 2012;9:621-30. [PMID: 22965149 DOI: 10.1038/nrclinonc.2012.159] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
235 Bosch-Vilaró A, Jacobs B, Pomella V, Abbasi Asbagh L, Kirkland R, Michel J, Singh S, Liu X, Kim P, Weitsman G, Barber PR, Vojnovic B, Ng T, Tejpar S. Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. Oncotarget 2017;8:4277-88. [PMID: 28032592 DOI: 10.18632/oncotarget.13834] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
236 Wang D, Hensman J, Kutkaite G, Toh TS, Galhoz A, Dry JR, Saez-Rodriguez J, Garnett MJ, Menden MP, Dondelinger F; GDSC Screening Team. A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates. Elife 2020;9:e60352. [PMID: 33274713 DOI: 10.7554/eLife.60352] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
237 Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med 2021;27:34-44. [PMID: 33442008 DOI: 10.1038/s41591-020-01195-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 18.0] [Reference Citation Analysis]
238 Wang C, Wang H, Lieftink C, du Chatinier A, Gao D, Jin G, Jin H, Beijersbergen RL, Qin W, Bernards R. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut 2020;69:727-36. [PMID: 31519701 DOI: 10.1136/gutjnl-2019-318506] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
239 Kayhanian H, Goode E, Sclafani F, Ang JE, Gerlinger M, Gonzalez de Castro D, Shepherd S, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N. Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Clin Colorectal Cancer. 2018;17:e69-e76. [PMID: 29129559 DOI: 10.1016/j.clcc.2017.10.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
240 Bando H, Yoshino T, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajiura S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A. Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. BMC Cancer 2013;13:405. [PMID: 24006859 DOI: 10.1186/1471-2407-13-405] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
241 Appleman VA, Ahronian LG, Cai J, Klimstra DS, Lewis BC. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Mol Cancer Res. 2012;10:1228-1239. [PMID: 22871572 DOI: 10.1158/1541-7786.mcr-12-0340-t] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
242 Joutei HAH, Marchoudi N, Mahfoud W, Sadaoui I, Fechtali T, Benomar H. Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients. Arab J Gastroenterol 2018;19:155-8. [PMID: 30503528 DOI: 10.1016/j.ajg.2018.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
243 Pazarentzos E, Bivona TG. Adaptive stress signaling in targeted cancer therapy resistance. Oncogene 2015;34:5599-606. [PMID: 25703329 DOI: 10.1038/onc.2015.26] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
244 Sealfon RSG, Wong AK, Troyanskaya OG. Machine learning methods to model multicellular complexity and tissue specificity. Nat Rev Mater 2021;6:717-29. [DOI: 10.1038/s41578-021-00339-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
245 Karapetis CS, Maru D, Waring P, Tie J, Michael MZ. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. Expert Rev Mol Diagn 2015;15:1033-48. [PMID: 26166616 DOI: 10.1586/14737159.2015.1052797] [Reference Citation Analysis]
246 Gbolahan O, O'Neil B. Update on systemic therapy for colorectal cancer: biologics take sides. Transl Gastroenterol Hepatol 2019;4:9. [PMID: 30976712 DOI: 10.21037/tgh.2019.01.12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
247 Jung G, Dover D, Salopek T. Risk of second primary malignancies following a diagnosis of cutaneous malignant melanoma or nonmelanoma skin cancer in Alberta, Canada from 1979 to 2009. Br J Dermatol 2014;170:136-43. [DOI: 10.1111/bjd.12694] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
248 Schayowitz A, Bertenshaw G, Jeffries E, Schatz T, Cotton J, Villanueva J, Herlyn M, Krepler C, Vultur A, Xu W, Yu GH, Schuchter L, Clark DP. Functional profiling of live melanoma samples using a novel automated platform. PLoS One 2012;7:e52760. [PMID: 23285177 DOI: 10.1371/journal.pone.0052760] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
249 Capalbo C, Marchetti P, Coppa A, Calogero A, Anastasi E, Buffone A, Belardinilli F, Gulino M, Frati P, Catalano C, Cortesi E, Giannini G, Gulino A. Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report. Cancer Biol Ther 2014;15:826-31. [PMID: 24755613 DOI: 10.4161/cbt.28878] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
250 Man R, Zhang Y, Jiang A, Zhu H. A patent review of RAF kinase inhibitors (2010–2018). Expert Opinion on Therapeutic Patents 2019;29:675-88. [DOI: 10.1080/13543776.2019.1651842] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
251 Pagliarini R, Shao W, Sellers WR. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 2015;16:280-296. [PMID: 25680965 DOI: 10.15252/embr.201439949] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 18.9] [Reference Citation Analysis]
252 Zou J, Lei T, Guo P, Yu J, Xu Q, Luo Y, Ke R, Huang D. Mechanisms shaping the role of ERK1/2 in cellular senescence (Review). Mol Med Rep 2019;19:759-70. [PMID: 30535440 DOI: 10.3892/mmr.2018.9712] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
253 Tatsuno M, Shioda Y, Iwafuchi H, Yamazaki S, Iijima K, Takahashi C, Ono H, Uchida K, Okamura O, Matubayashi M, Okuyama T, Matsumoto K, Yoshioka T, Nakazawa A. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay. Diagn Pathol 2016;11:39. [PMID: 27094161 DOI: 10.1186/s13000-016-0489-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
254 Park S, Lehner B. Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types. Mol Syst Biol 2015;11:824. [PMID: 26227665 DOI: 10.15252/msb.20156102] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
255 Wells SA Jr, Santoro M. Update: the status of clinical trials with kinase inhibitors in thyroid cancer. J Clin Endocrinol Metab 2014;99:1543-55. [PMID: 24423326 DOI: 10.1210/jc.2013-2622] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
256 Langdon CG, Held MA, Platt JT, Meeth K, Iyidogan P, Mamillapalli R, Koo AB, Klein M, Liu Z, Bosenberg MW, Stern DF. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors. Pigment Cell Melanoma Res 2015;28:417-30. [PMID: 25854919 DOI: 10.1111/pcmr.12376] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
257 Diedrich B, Rigbolt KT, Röring M, Herr R, Kaeser-Pebernard S, Gretzmeier C, Murphy RF, Brummer T, Dengjel J. Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition. EMBO J 2017;36:646-63. [PMID: 28093501 DOI: 10.15252/embj.201694732] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
258 Notarangelo T, Sisinni L, Trino S, Calice G, Simeon V, Landriscina M. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. Cancer Lett 2018;433:147-55. [PMID: 29969659 DOI: 10.1016/j.canlet.2018.06.038] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
259 Lee DS, O'Keefe RA, Ha PK, Grandis JR, Johnson DE. Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. Int J Mol Sci 2018;19:E1608. [PMID: 29848966 DOI: 10.3390/ijms19061608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
260 Alifrangis CC, McDermott U. Reading between the lines; understanding drug response in the post genomic era. Mol Oncol 2014;8:1112-9. [PMID: 24957465 DOI: 10.1016/j.molonc.2014.05.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
261 Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. J Thorac Oncol 2015;10:1451-7. [PMID: 26200454 DOI: 10.1097/JTO.0000000000000625] [Cited by in Crossref: 92] [Cited by in F6Publishing: 46] [Article Influence: 15.3] [Reference Citation Analysis]
262 Baraibar I, Mirallas O, Saoudi N, Ros J, Salvà F, Tabernero J, Élez E. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:6311. [PMID: 34944931 DOI: 10.3390/cancers13246311] [Reference Citation Analysis]
263 Ozturk K, Dow M, Carlin DE, Bejar R, Carter H. The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine. J Mol Biol 2018;430:2875-99. [PMID: 29908887 DOI: 10.1016/j.jmb.2018.06.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 8.8] [Reference Citation Analysis]
264 Huang M, Shen A, Ding J, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci 2014;35:41-50. [PMID: 24361003 DOI: 10.1016/j.tips.2013.11.004] [Cited by in Crossref: 186] [Cited by in F6Publishing: 159] [Article Influence: 20.7] [Reference Citation Analysis]
265 Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014;8:1095-111. [PMID: 25087573 DOI: 10.1016/j.molonc.2014.06.005] [Cited by in Crossref: 265] [Cited by in F6Publishing: 220] [Article Influence: 33.1] [Reference Citation Analysis]
266 Silkin SV, Startsev SS, Krasnova ME, Raskin GA, Mitiushkina NV, Iyevleva AG, Sokolenko AP, Imyanitov EN. Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan. J Gastrointest Cancer 2016;47:502-5. [PMID: 26687137 DOI: 10.1007/s12029-015-9792-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
267 Kemp JA, Shim MS, Heo CY, Kwon YJ. “Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Advanced Drug Delivery Reviews 2016;98:3-18. [DOI: 10.1016/j.addr.2015.10.019] [Cited by in Crossref: 269] [Cited by in F6Publishing: 255] [Article Influence: 44.8] [Reference Citation Analysis]
268 Allen F, Behan F, Khodak A, Iorio F, Yusa K, Garnett M, Parts L. JACKS: joint analysis of CRISPR/Cas9 knockout screens. Genome Res 2019;29:464-71. [PMID: 30674557 DOI: 10.1101/gr.238923.118] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
269 Tutuncuoglu B, Krogan NJ. Mapping genetic interactions in cancer: a road to rational combination therapies. Genome Med 2019;11:62. [PMID: 31640753 DOI: 10.1186/s13073-019-0680-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
270 Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov. 2015;5:358-367. [PMID: 25673644 DOI: 10.1158/2159-8290.cd-14-1518] [Cited by in Crossref: 186] [Cited by in F6Publishing: 119] [Article Influence: 26.6] [Reference Citation Analysis]
271 Bernabe-Ramirez C, Patel R, Chahal J, Saif MW. Treatment options in BRAF-mutant metastatic colorectal cancer. Anticancer Drugs. 2020;31:545-557. [PMID: 32304411 DOI: 10.1097/cad.0000000000000940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
272 Posternak G, Tang X, Maisonneuve P, Jin T, Lavoie H, Daou S, Orlicky S, Goullet de Rugy T, Caldwell L, Chan K, Aman A, Prakesch M, Poda G, Mader P, Wong C, Maier S, Kitaygorodsky J, Larsen B, Colwill K, Yin Z, Ceccarelli DF, Batey RA, Taipale M, Kurinov I, Uehling D, Wrana J, Durocher D, Gingras AC, Al-Awar R, Therrien M, Sicheri F. Functional characterization of a PROTAC directed against BRAF mutant V600E. Nat Chem Biol 2020;16:1170-8. [PMID: 32778845 DOI: 10.1038/s41589-020-0609-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
273 Ponsioen B, Post JB, Buissant des Amorie JR, Laskaris D, van Ineveld RL, Kersten S, Bertotti A, Sassi F, Sipieter F, Cappe B, Mertens S, Verlaan-Klink I, Boj SF, Vries RGJ, Rehmann H, Vandenabeele P, Riquet FB, Trusolino L, Bos JL, Snippert HJG. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling. Nat Cell Biol 2021;23:377-90. [PMID: 33795873 DOI: 10.1038/s41556-021-00654-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
274 Affolter K, Samowitz W, Tripp S, Bronner MP. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. Genes Chromosomes Cancer. 2013;52:748-752. [PMID: 23650027 DOI: 10.1002/gcc.22070] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
275 Meierjohann S. Crosstalk signaling in targeted melanoma therapy. Cancer Metastasis Rev 2017;36:23-33. [PMID: 28197745 DOI: 10.1007/s10555-017-9659-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
276 Jürgensmeier JM, Eder JP, Herbst RS. New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin Cancer Res 2014;20:4425-35. [PMID: 25183480 DOI: 10.1158/1078-0432.CCR-13-0753] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
277 Huang A, Garraway LA, Ashworth A, Weber B. Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov 2020;19:23-38. [DOI: 10.1038/s41573-019-0046-z] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 33.0] [Reference Citation Analysis]
278 Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6:988-1038. [PMID: 24276379 DOI: 10.3390/ph6080988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
279 Plotnikov A, Flores K, Maik-Rachline G, Zehorai E, Kapri-Pardes E, Berti DA, Hanoch T, Besser MJ, Seger R. The nuclear translocation of ERK1/2 as an anticancer target. Nat Commun 2015;6:6685. [PMID: 25819065 DOI: 10.1038/ncomms7685] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
280 Mock A, Murphy S, Morris J, Marass F, Rosenfeld N, Massie C. CVE: an R package for interactive variant prioritisation in precision oncology. BMC Med Genomics 2017;10:37. [PMID: 28545463 DOI: 10.1186/s12920-017-0261-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
281 See WL, Mukherjee J. Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy. Elsevier; 2018. pp. 323-32. [DOI: 10.1016/b978-0-12-812100-9.00022-x] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
282 Topol EJ. Individualized medicine from prewomb to tomb. Cell 2014;157:241-53. [PMID: 24679539 DOI: 10.1016/j.cell.2014.02.012] [Cited by in Crossref: 175] [Cited by in F6Publishing: 138] [Article Influence: 21.9] [Reference Citation Analysis]
283 Sabry D, Ahmed R, Abdalla S, Fathy W, Eldemery A, Elamir A. Braf, Kras and Helicobacter pylori epigenetic changes-associated chronic gastritis in Egyptian patients with and without gastric cancer. World J Microbiol Biotechnol 2016;32:92. [PMID: 27116958 DOI: 10.1007/s11274-016-2048-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
284 Dorel M, Klinger B, Mari T, Toedling J, Blanc E, Messerschmidt C, Nadler-Holly M, Ziehm M, Sieber A, Hertwig F, Beule D, Eggert A, Schulte JH, Selbach M, Blüthgen N. Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. PLoS Comput Biol 2021;17:e1009515. [PMID: 34735429 DOI: 10.1371/journal.pcbi.1009515] [Reference Citation Analysis]
285 Bernards R. A Missing Link in Genotype-Directed Cancer Therapy. Cell 2012;151:465-8. [DOI: 10.1016/j.cell.2012.10.014] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
286 Lin VTG, Yang ES. The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology. J Natl Cancer Inst 2019;111:1016-22. [PMID: 31165154 DOI: 10.1093/jnci/djz114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
287 Greystoke A, Chaturvedi A. An introduction to stratified medicine. Drug Discovery Today 2015;20:1409-13. [DOI: 10.1016/j.drudis.2015.07.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
288 Sparidans RW, Rosing H, Rood JJM, Schellens JHM, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1033-1034:390-8. [PMID: 27639128 DOI: 10.1016/j.jchromb.2016.09.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
289 Munoz J, Kurzrock R. Targeted therapy in rare cancers—adopting the orphans. Nat Rev Clin Oncol 2012;9:631-42. [DOI: 10.1038/nrclinonc.2012.160] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
290 Irmisch A, Bonilla X, Chevrier S, Lehmann KV, Singer F, Toussaint NC, Esposito C, Mena J, Milani ES, Casanova R, Stekhoven DJ, Wegmann R, Jacob F, Sobottka B, Goetze S, Kuipers J, Sarabia Del Castillo J, Prummer M, Tuncel MA, Menzel U, Jacobs A, Engler S, Sivapatham S, Frei AL, Gut G, Ficek J, Miglino N, Aebersold R, Bacac M, Beerenwinkel N, Beisel C, Bodenmiller B, Dummer R, Heinzelmann-Schwarz V, Koelzer VH, Manz MG, Moch H, Pelkmans L, Snijder B, Theocharides APA, Tolnay M, Wicki A, Wollscheid B, Rätsch G, Levesque MP; Tumor Profiler Consortium. The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell 2021;39:288-93. [PMID: 33482122 DOI: 10.1016/j.ccell.2021.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
291 Sasankan S, Rebuck L, Darrah G, Harari Turquie M, Rabinowitz I. Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy. Case Rep Oncol 2020;13:1239-43. [PMID: 33250737 DOI: 10.1159/000510096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
292 Nagaraja AK, Bass AJ. Hitting the Target in BRAF -Mutant Colorectal Cancer. JCO 2015;33:3990-2. [DOI: 10.1200/jco.2015.63.7793] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
293 Meierjohann S. Effect of stress-induced polyploidy on melanoma reprogramming and therapy resistance. Semin Cancer Biol 2021:S1044-579X(21)00028-6. [PMID: 33610722 DOI: 10.1016/j.semcancer.2021.02.005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
294 Grassi E, Corbelli J, Papiani G, Barbera MA, Gazzaneo F, Tamberi S. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Front Oncol 2021;11:601722. [PMID: 34249672 DOI: 10.3389/fonc.2021.601722] [Reference Citation Analysis]
295 Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res 2021;40:328. [PMID: 34663410 DOI: 10.1186/s13046-021-02130-2] [Reference Citation Analysis]
296 Uitdehaag JC, de Roos JA, van Doornmalen AM, Prinsen MB, Spijkers-Hagelstein JA, de Vetter JR, de Man J, Buijsman RC, Zaman GJ. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS One 2015;10:e0125021. [PMID: 26018524 DOI: 10.1371/journal.pone.0125021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
297 Joshi M, Rice SJ, Liu X, Miller B, Belani CP. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. PLoS One 2015;10:e0118210. [PMID: 25706985 DOI: 10.1371/journal.pone.0118210] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
298 Xu G, Shi H, Ren L, Gou H, Gong D, Gao X, Huang N. Enhancing the anti-colon cancer activity of quercetin by self-assembled micelles. Int J Nanomedicine 2015;10:2051-63. [PMID: 25844036 DOI: 10.2147/IJN.S75550] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
299 Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol 2012;65:335-59. [PMID: 22959031 DOI: 10.1016/B978-0-12-397927-8.00011-7] [Cited by in Crossref: 59] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
300 Sleijfer S, Bogaerts J, Siu LL. Designing Transformative Clinical Trials in the Cancer Genome Era. JCO 2013;31:1834-41. [DOI: 10.1200/jco.2012.45.3639] [Cited by in Crossref: 120] [Cited by in F6Publishing: 58] [Article Influence: 13.3] [Reference Citation Analysis]
301 Peng W, Hu J, Zhu XD, Liu X, Wang CC, Li WH, Chen ZY. Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. Tumour Biol 2014;35:2983-8. [PMID: 24248543 DOI: 10.1007/s13277-013-1383-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
302 Ruggeri BA, Camp F, Miknyoczki S. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol 2014;87:150-61. [PMID: 23817077 DOI: 10.1016/j.bcp.2013.06.020] [Cited by in Crossref: 194] [Cited by in F6Publishing: 159] [Article Influence: 21.6] [Reference Citation Analysis]
303 Simonelli M, Zucali PA, Lorenzi E, Rubino L, De Vincenzo F, De Sanctis R, Perrino M, Mancini L, Di Tommaso L, Rimassa L, Masci G, Zuradelli M, Suter MB, Bertossi M, Fattuzzo G, Giordano L, Roncalli MG, Santoro A. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors. European Journal of Cancer 2013;49:989-98. [DOI: 10.1016/j.ejca.2012.10.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
304 Prasad CP, Mohapatra P, Andersson T. Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer? Cancers (Basel) 2015;7:1900-24. [PMID: 26393652 DOI: 10.3390/cancers7030868] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
305 Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Mol Cancer Ther 2015;14:2700-11. [PMID: 26351322 DOI: 10.1158/1535-7163.MCT-15-0136-T] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 5.9] [Reference Citation Analysis]
306 Leung AW, Kalra J, Santos ND, Bally MB, Anglesio MS. Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. Nanomedicine (Lond) 2014;9:501-22. [PMID: 24746193 DOI: 10.2217/nnm.13.220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
307 Tessier-Cloutier B, Cai E, Schaeffer DF. Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. Diagn Pathol 2019;14:62. [PMID: 31221175 DOI: 10.1186/s13000-019-0843-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
308 Hoefflin R, Geißler AL, Fritsch R, Claus R, Wehrle J, Metzger P, Reiser M, Mehmed L, Fauth L, Heiland DH, Erbes T, Stock F, Csanadi A, Miething C, Weddeling B, Meiss F, von Bubnoff D, Dierks C, Ge I, Brass V, Heeg S, Schäfer H, Boeker M, Rawluk J, Botzenhart EM, Kayser G, Hettmer S, Busch H, Peters C, Werner M, Duyster J, Brummer T, Boerries M, Lassmann S, von Bubnoff N. Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience. JCO Precis Oncol 2018;2:PO. [PMID: 32913998 DOI: 10.1200/PO.18.00105] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
309 Alexander PB, Wang XF. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies. Front Med 2015;9:134-8. [PMID: 25957263 DOI: 10.1007/s11684-015-0396-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
310 Stewart A, Coker EA, Pölsterl S, Georgiou A, Minchom AR, Carreira S, Cunningham D, O'Brien ME, Raynaud FI, de Bono JS, Al-Lazikani B, Banerji U. Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. Mol Cancer Ther 2019;18:1396-404. [PMID: 31262731 DOI: 10.1158/1535-7163.MCT-18-0727] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
311 Cerrito MG, Grassilli E. Identifying Novel Actionable Targets in Colon Cancer. Biomedicines 2021;9:579. [PMID: 34065438 DOI: 10.3390/biomedicines9050579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 Thomas F, Desmedt C, Aftimos P, Awada A. Impact of tumor sequencing on the use of anticancer drugs. Curr Opin Oncol. 2014;26:347-356. [PMID: 24709974 DOI: 10.1097/cco.0000000000000078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
313 Cremolini C, Pietrantonio F. How the lab is changing our view of colorectal cancer. Tumori 2016;102:541-7. [PMID: 27647226 DOI: 10.5301/tj.5000551] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
314 Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer. 2014;50:57-63. [PMID: 24138831 DOI: 10.1016/j.ejca.2013.08.024] [Cited by in Crossref: 123] [Cited by in F6Publishing: 107] [Article Influence: 13.7] [Reference Citation Analysis]
315 Orlov SV, Urtenova MA, Sviridenko MA, Nesterov DV, Sokolova TN, Imyanitov EN. Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab.Case Rep Oncol. 2020;13:985-989. [PMID: 32999660 DOI: 10.1159/000509241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
316 Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. J Exp Clin Cancer Res 2018;37:140. [PMID: 29986755 DOI: 10.1186/s13046-018-0820-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
317 Tan DS, Mok TS, Rebbeck TR. Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. J Clin Oncol 2016;34:91-101. [PMID: 26578615 DOI: 10.1200/JCO.2015.62.0096] [Cited by in Crossref: 89] [Cited by in F6Publishing: 59] [Article Influence: 12.7] [Reference Citation Analysis]
318 Seow HF, Yip WK, Fifis T. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016;9:1899-920. [PMID: 27099521 DOI: 10.2147/OTT.S95101] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
319 Gao Y, Vallentgoed WR, French PJ. Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas. Cancers (Basel) 2018;10:E489. [PMID: 30518123 DOI: 10.3390/cancers10120489] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
320 Ofir Dovrat T, Sokol E, Frampton G, Shachar E, Pelles S, Geva R, Wolf I. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Cancer Biol Ther 2018;19:871-4. [PMID: 30036146 DOI: 10.1080/15384047.2018.1480289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
321 Theiss AP, Chafin D, Bauer DR, Grogan TM, Baird GS. Immunohistochemistry of colorectal cancer biomarker phosphorylation requires controlled tissue fixation. PLoS One 2014;9:e113608. [PMID: 25409462 DOI: 10.1371/journal.pone.0113608] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
322 Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson RM, Cencic R, Patibandla J, Chen H, Papadakis AI, Auguste A, de Rink I, Kerkhoven RM, Bertos N, Gotlieb WH, Clarke BA, Leary A, Witcher M, Guiot MC, Pelletier J, Dostie J, Park M, Judkins AR, Hass R, Levine DA, Rak J, Vanderhyden B, Foulkes WD, Huang S. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. Nat Commun 2019;10:558. [PMID: 30718512 DOI: 10.1038/s41467-018-06958-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
323 Guo D, Bell EH, Mischel P, Chakravarti A. Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Des 2014;20:2619-26. [PMID: 23859617 DOI: 10.2174/13816128113199990486] [Cited by in Crossref: 124] [Cited by in F6Publishing: 125] [Article Influence: 17.7] [Reference Citation Analysis]
324 Hirata E, Sahai E. Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harb Perspect Med 2017;7:a026781. [PMID: 28213438 DOI: 10.1101/cshperspect.a026781] [Cited by in Crossref: 130] [Cited by in F6Publishing: 120] [Article Influence: 26.0] [Reference Citation Analysis]
325 Wang C, Zhang Y, Guo K, Wang N, Jin H, Liu Y, Qin W. Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential. Int J Cancer. 2016;138:1824-1834. [PMID: 26853533 DOI: 10.1002/ijc.29723] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
326 Fellmann C, Lowe SW. Stable RNA interference rules for silencing. Nat Cell Biol 2014;16:10-8. [PMID: 24366030 DOI: 10.1038/ncb2895] [Cited by in Crossref: 123] [Cited by in F6Publishing: 109] [Article Influence: 15.4] [Reference Citation Analysis]
327 Hiraide S, Takahashi M, Yoshida Y, Yamada H, Komine K, Ishioka C. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer. Cancer Sci 2021;112:3856-70. [PMID: 34288281 DOI: 10.1111/cas.15075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
328 Kirouac DC, Schaefer G, Chan J, Merchant M, Orr C, Huang SA, Moffat J, Liu L, Gadkar K, Ramanujan S. Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model. NPJ Syst Biol Appl 2017;3:14. [PMID: 28649441 DOI: 10.1038/s41540-017-0016-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
329 Virzì AR, Gentile A, Benvenuti S, Comoglio PM. Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. Proc Natl Acad Sci U S A 2018;115:10058-63. [PMID: 30224486 DOI: 10.1073/pnas.1721147115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
330 Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res 2014;20:2264-75. [PMID: 24599935 DOI: 10.1158/1078-0432.CCR-13-1591] [Cited by in Crossref: 45] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
331 Liu J, Wang Z. Diverse array-designed modes of combination therapies in Fangjiomics. Acta Pharmacol Sin 2015;36:680-8. [PMID: 25864646 DOI: 10.1038/aps.2014.125] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
332 Diab M. Shedding Light on BRAF: Management of Colorectal Cancer in the Era of Personalized Medicine. JCO Oncol Pract 2021;:OP2100467. [PMID: 34324371 DOI: 10.1200/OP.21.00467] [Reference Citation Analysis]
333 Wang X, Markowetz F, De Sousa E Melo F, Medema JP, Vermeulen L. Dissecting cancer heterogeneity--an unsupervised classification approach. Int J Biochem Cell Biol 2013;45:2574-9. [PMID: 24004832 DOI: 10.1016/j.biocel.2013.08.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
334 Graziani V, Esposito A, Scognamiglio M, Chambery A, Russo R, Ciardiello F, Troiani T, Potenza N, Fiorentino A, D'Abrosca B. Spectroscopic Characterization and Cytotoxicity Assessment towards Human Colon Cancer Cell Lines of Acylated Cycloartane Glycosides from Astragalus boeticus L. Molecules 2019;24:E1725. [PMID: 31058835 DOI: 10.3390/molecules24091725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
335 McArthur GA. Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet. Front Oncol 2015;5:161. [PMID: 26236691 DOI: 10.3389/fonc.2015.00161] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
336 Yang Y, Zhu F, Wang Q, Ding Y, Ying R, Zeng L. Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells. Onco Targets Ther 2018;11:8455-63. [PMID: 30555238 DOI: 10.2147/OTT.S186498] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
337 Eck MJ, Hahn WC. EGFR in limbo. Cell 2012;149:735-7. [PMID: 22579278 DOI: 10.1016/j.cell.2012.04.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
338 Frasca F, Vella V, Nicolosi ML, Messina RL, Gianì F, Lotta S, Vigneri P, Regalbuto C, Vigneri R. Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. J Clin Endocrinol Metab 2013;98:2502-12. [PMID: 23559083 DOI: 10.1210/jc.2012-3623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
339 Hinterndorfer M, Zuber J. Functional-genetic approaches to understanding drug response and resistance. Curr Opin Genet Dev 2019;54:41-7. [PMID: 30951975 DOI: 10.1016/j.gde.2019.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
340 Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol. 2013;31:e341-e344. [PMID: 23733758 DOI: 10.1200/jco.2012.47.6143] [Cited by in Crossref: 82] [Cited by in F6Publishing: 34] [Article Influence: 9.1] [Reference Citation Analysis]
341 Le AT, Doebele RC. The democratization of the oncogene. Cancer Discov 2014;4:870-2. [PMID: 25092743 DOI: 10.1158/2159-8290.CD-14-0628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
342 Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 2014;14:258. [PMID: 24725538 DOI: 10.1186/1471-2407-14-258] [Cited by in Crossref: 133] [Cited by in F6Publishing: 107] [Article Influence: 16.6] [Reference Citation Analysis]
343 Jin T, Lavoie H, Sahmi M, David M, Hilt C, Hammell A, Therrien M. RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition. Nat Commun 2017;8:1211. [PMID: 29084939 DOI: 10.1038/s41467-017-01274-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
344 Biswas S, Holyoake D, Maughan T. Molecular Taxonomy and Tumourigenesis of Colorectal Cancer. Clinical Oncology 2016;28:73-82. [DOI: 10.1016/j.clon.2015.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
345 Ros J, Baraibar I, Martini G, Salvà F, Saoudi N, Cuadra-Urteaga JL, Dienstmann R, Tabernero J, Élez E. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Curr Treat Options Oncol 2021;22:113. [PMID: 34741675 DOI: 10.1007/s11864-021-00913-5] [Reference Citation Analysis]
346 Wilson MK, Collyar D, Chingos DT, Friedlander M, Ho TW, Karakasis K, Kaye S, Parmar MK, Sydes MR, Tannock IF, Oza AM. Outcomes and endpoints in cancer trials: bridging the divide. Lancet Oncol 2015;16:e43-52. [PMID: 25638556 DOI: 10.1016/S1470-2045(14)70380-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
347 Rustgi A. BRAF: A Driver of the Serrated Pathway in Colon Cancer. Cancer Cell 2013;24:1-2. [DOI: 10.1016/j.ccr.2013.06.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
348 Tie J, Desai J. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Target Oncol. 2015;10:179-188. [PMID: 25119972 DOI: 10.1007/s11523-014-0330-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
349 Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2012;97:2566-72. [PMID: 22869844 DOI: 10.1210/jc.2012-1314] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
350 Gay L, Baker AM, Graham TA. Tumour Cell Heterogeneity. F1000Res. 2016;5:pii F1000. [PMID: 26973786 DOI: 10.12688/f1000research.7210.1] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
351 Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol Cancer Res 2016;14:3-13. [PMID: 26248648 DOI: 10.1158/1541-7786.MCR-15-0189] [Cited by in Crossref: 145] [Cited by in F6Publishing: 82] [Article Influence: 20.7] [Reference Citation Analysis]
352 Kancherla J, Rao S, Bhuvaneshwar K, Riggins RB, Beckman RA, Madhavan S, Corrada Bravo H, Boca SM. Evidence-Based Network Approach to Recommending Targeted Cancer Therapies. JCO Clin Cancer Inform 2020;4:71-88. [PMID: 31990579 DOI: 10.1200/CCI.19.00097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
353 Stites EC. Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition. Methods Mol Biol 2021;2262:311-21. [PMID: 33977486 DOI: 10.1007/978-1-0716-1190-6_19] [Reference Citation Analysis]
354 Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Sweep FC, Geurts-Moespot A, Engelhardt MS, van der Graaf WT, Oyen WJ, van Laarhoven HW. Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression. Mol Pharm 2014;11:4249-57. [PMID: 25294389 DOI: 10.1021/mp500460g] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
355 Notarangelo T, Sisinni L, Condelli V, Landriscina M. Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells. Cancer Cell Int 2017;17:86. [PMID: 29033690 DOI: 10.1186/s12935-017-0457-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
356 Das M, Musetti S, Huang L. RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise. Nucleic Acid Ther 2019;29:61-6. [PMID: 30562145 DOI: 10.1089/nat.2018.0762] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
357 Kranz LM, Birtel M, Krienke C, Grunwitz C, Petschenka J, Reuter KC, van de Roemer N, Vascotto F, Vormehr M, Kreiter S, Diken M. CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy. Hum Vaccin Immunother 2016;12:213-21. [PMID: 26186022 DOI: 10.1080/21645515.2015.1068485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
358 Foster J, Freidlin B, Korn EL, Smith M. Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity. ESMO Open 2020;5:e000871. [PMID: 33122353 DOI: 10.1136/esmoopen-2020-000871] [Reference Citation Analysis]
359 Truong AY, Nicolaides TP. Targeted Therapy for MAPK Alterations in Pediatric Gliomas. Brain Disord Ther 2015;Suppl 2:005. [PMID: 26525348 DOI: 10.4172/2168-975X.S2-005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
360 Rihawi K, Giampieri R, Scartozzi M, Pusceddu V, Bonotto M, Fasola G, Cascinu S, Aprile G. Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. Expert Opinion on Investigational Drugs 2015;24:1185-98. [DOI: 10.1517/13543784.2015.1054479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
361 Vétillard A, Jonchère B, Moreau M, Toutain B, Henry C, Fontanel S, Bernard AC, Campone M, Guette C, Coqueret O. Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis. Oncotarget 2015;6:43342-62. [PMID: 26485768 DOI: 10.18632/oncotarget.6126] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
362 Conway AM, Mitchell C, Kilgour E, Brady G, Dive C, Cook N. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'. Br J Cancer 2019;120:141-53. [PMID: 30580378 DOI: 10.1038/s41416-018-0332-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
363 Santoro M, Carlomagno F. Attacking cancer with molecularly targeted agents. Curr Opin Pharmacol 2013;13:483-5. [PMID: 23871444 DOI: 10.1016/j.coph.2013.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
364 Bible KC, Cote GJ, Demeure MJ, Elisei R, Jhiang S, Ringel MD; International Thyroid Oncology Group Correlative Science Committee. Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. J Clin Endocrinol Metab 2015;100:4387-95. [PMID: 26418285 DOI: 10.1210/jc.2015-2818] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
365 Izar B, Rotow J, Gainor J, Clark J, Chabner B, Longo DL. Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacol Rev 2013;65:1351-95. [DOI: 10.1124/pr.113.007807] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
366 Sos ML, Dietlein F, Peifer M, Schöttle J, Balke-Want H, Müller C, Koker M, Richters A, Heynck S, Malchers F. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci USA. 2012;109:17034-17039. [PMID: 23035247 DOI: 10.1073/pnas.1207310109] [Cited by in Crossref: 119] [Cited by in F6Publishing: 107] [Article Influence: 11.9] [Reference Citation Analysis]
367 Wang Y, Sun S, Luo J, Xiong Y, Ming T, Liu J, Ma Y, Yan S, Yang Y, Yang Z, Reboud J, Yin H, Cooper JM, Cai X. Low sample volume origami-paper-based graphene-modified aptasensors for label-free electrochemical detection of cancer biomarker-EGFR. Microsyst Nanoeng 2020;6:32. [PMID: 34567646 DOI: 10.1038/s41378-020-0146-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
368 Protsenko SA, Semionova AI, Komarov YI, Aleksakhina SN, Ivantsov AO, Iyevleva AG, Imyanitov EN. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Invest New Drugs 2015;33:1136-43. [DOI: 10.1007/s10637-015-0280-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
369 Henkel L, Rauscher B, Boutros M. Context-dependent genetic interactions in cancer. Curr Opin Genet Dev 2019;54:73-82. [PMID: 31026747 DOI: 10.1016/j.gde.2019.03.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
370 García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin Cancer Res 2015;21:5499-510. [PMID: 26272063 DOI: 10.1158/1078-0432.CCR-14-3091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
371 Stites EC. The response of cancers to BRAF inhibition underscores the importance of cancer systems biology. Sci Signal 2012;5:pe46. [PMID: 23074264 DOI: 10.1126/scisignal.2003354] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
372 Hight SK, Mootz A, Kollipara RK, McMillan E, Yenerall P, Otaki Y, Li LS, Avila K, Peyton M, Rodriguez-Canales J, Mino B, Villalobos P, Girard L, Dospoy P, Larsen J, White MA, Heymach JV, Wistuba II, Kittler R, Minna JD. An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. Neoplasia 2020;22:294-310. [PMID: 32512502 DOI: 10.1016/j.neo.2020.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
373 Bröckelmann PJ, de Jong MRW, Jachimowicz RD. Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma. Cells 2020;9:E2287. [PMID: 33066395 DOI: 10.3390/cells9102287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
374 Lubner SJ, Uboha NV, Deming DA. Primary and acquired resistance to biologic therapies in gastrointestinal cancers. J Gastrointest Oncol 2017;8:499-512. [PMID: 28736637 DOI: 10.21037/jgo.2017.01.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
375 Prescott JA, Mitchell JP, Cook SJ. Inhibitory feedback control of NF-κB signalling in health and disease. Biochem J 2021;478:2619-64. [PMID: 34269817 DOI: 10.1042/BCJ20210139] [Reference Citation Analysis]
376 Weiss GJ. Precision medicine: lessons learned from the SHIVA trial. The Lancet Oncology 2015;16:e580. [DOI: 10.1016/s1470-2045(15)00387-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
377 Kaligotla VSA, Jasti T, Kandra P. CRISPR/Cas9 in cancer: An attempt to the present trends and future prospects. Biotechnol Appl Biochem 2021. [PMID: 34033692 DOI: 10.1002/bab.2200] [Reference Citation Analysis]
378 Czauderna C, Kirstein MM, Tews HC, Vogel A, Marquardt JU. Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2803. [PMID: 34202401 DOI: 10.3390/jcm10132803] [Reference Citation Analysis]
379 Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer MJ, Araki K, Ozerdem U, Simeone DM, Miller G, Neel BG, Tang KH. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discov 2018;8:1237-49. [PMID: 30045908 DOI: 10.1158/2159-8290.CD-18-0444] [Cited by in Crossref: 94] [Cited by in F6Publishing: 62] [Article Influence: 23.5] [Reference Citation Analysis]
380 Ressa A, Bosdriesz E, de Ligt J, Mainardi S, Maddalo G, Prahallad A, Jager M, de la Fonteijne L, Fitzpatrick M, Groten S, Altelaar AFM, Bernards R, Cuppen E, Wessels L, Heck AJR. A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells. Mol Cell Proteomics 2018;17:1892-908. [PMID: 29970458 DOI: 10.1074/mcp.RA117.000486] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
381 Heikinheimo K, Kurppa KJ, Elenius K. Novel targets for the treatment of ameloblastoma. J Dent Res 2015;94:237-40. [PMID: 25425580 DOI: 10.1177/0022034514560373] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
382 Zhao D, Chen J, Wang Y, Zhang L, Zhang J, Zhang W, Fan J, Li J, Zhan Q. Feed-forward activation of STAT3 signaling limits the efficacy of c-Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment. Mol Carcinog 2021;60:481-96. [PMID: 34018249 DOI: 10.1002/mc.23306] [Reference Citation Analysis]
383 Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med. 2014;6:224ra26. [PMID: 24553387 DOI: 10.1126/scitranslmed.3007947] [Cited by in Crossref: 174] [Cited by in F6Publishing: 157] [Article Influence: 21.8] [Reference Citation Analysis]
384 Goldberg RM. Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions? Oncologist 2015;20:1448-56. [PMID: 26512044 DOI: 10.1634/theoncologist.2015-0263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
385 Anastasi S, Lamberti D, Alemà S, Segatto O. Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics. Semin Cell Dev Biol 2016;50:115-24. [PMID: 26456277 DOI: 10.1016/j.semcdb.2015.10.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
386 Rozengurt E, Soares HP, Sinnet-Smith J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther. 2014;13:2477-2488. [PMID: 25323681 DOI: 10.1158/1535-7163.mct-14-0330] [Cited by in Crossref: 145] [Cited by in F6Publishing: 91] [Article Influence: 18.1] [Reference Citation Analysis]
387 Connolly K, Brungs D, Szeto E, Epstein RJ. Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma. Curr Oncol 2014;21:e151-4. [PMID: 24523613 DOI: 10.3747/co.21.1661] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
388 Sundar R, Hong DS, Kopetz S, Yap TA. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discov 2017;7:558-60. [PMID: 28576843 DOI: 10.1158/2159-8290.CD-17-0087] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
389 Jaeger S, Duran-Frigola M, Aloy P. Drug sensitivity in cancer cell lines is not tissue-specific. Mol Cancer 2015;14:40. [PMID: 25881072 DOI: 10.1186/s12943-015-0312-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
390 Shaib W, Mahajan R, El-Rayes B. Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol 2013;4:308-18. [PMID: 23997942 DOI: 10.3978/j.issn.2078-6891.2013.029] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
391 Nakayama I, Hirota T, Shinozaki E. BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers (Basel) 2020;12:E3236. [PMID: 33152998 DOI: 10.3390/cancers12113236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
392 Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol 2015;17:804-15. [PMID: 26005835 DOI: 10.1038/ncb3175] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
393 Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience 2014;1:614-23. [PMID: 25593991 DOI: 10.18632/oncoscience.90] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
394 Turajlic S, Ali Z, Yousaf N, Larkin J. Phase I/II RAF kinase inhibitors in cancer therapy. Expert Opin Investig Drugs 2013;22:739-49. [PMID: 23642225 DOI: 10.1517/13543784.2013.797964] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
395 Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer Sci 2020;111:441-50. [PMID: 31821662 DOI: 10.1111/cas.14273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
396 Lehmann-Che J, Poirot B, Boyer JC, Evrard A. Cancer genomics guide clinical practice in personalized medicine. Therapie 2017;72:439-51. [PMID: 28258721 DOI: 10.1016/j.therap.2016.09.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
397 Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 2020;17:11-32. [PMID: 31289352 DOI: 10.1038/s41571-019-0241-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 22.3] [Reference Citation Analysis]
398 Ma J, Fong SH, Luo Y, Bakkenist CJ, Shen JP, Mourragui S, Wessels LFA, Hafner M, Sharan R, Peng J, Ideker T. Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients. Nat Cancer 2021;2:233-44. [PMID: 34223192 DOI: 10.1038/s43018-020-00169-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
399 Hammond DE, Mageean CJ, Rusilowicz EV, Wickenden JA, Clague MJ, Prior IA. Differential reprogramming of isogenic colorectal cancer cells by distinct activating KRAS mutations. J Proteome Res 2015;14:1535-46. [PMID: 25599653 DOI: 10.1021/pr501191a] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
400 Wang C, Liao Y, He W, Zhang H, Zuo D, Liu W, Yang Z, Qiu J, Yuan Y, Li K, Zhang Y, Wang Y, Shi Y, Qiu Y, Gao S, Yuan Y, Li B. Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma. J Exp Clin Cancer Res 2021;40:113. [PMID: 33771199 DOI: 10.1186/s13046-021-01904-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
401 Martin S, Dudek-perić A, Maes H, Garg A, Gabrysiak M, Demirsoy S, Swinnen J, Agostinis P. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. Biochemical Pharmacology 2015;93:290-304. [DOI: 10.1016/j.bcp.2014.12.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
402 Carbonell P, Trosset JY. Overcoming drug resistance through in silico prediction. Drug Discov Today Technol 2014;11:101-7. [PMID: 24847659 DOI: 10.1016/j.ddtec.2014.03.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
403 Schweppe RE. Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets. Front Endocrinol (Lausanne) 2012;3:81. [PMID: 22723793 DOI: 10.3389/fendo.2012.00081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
404 Wang SJ, Li R, Ng TSC, Luthria G, Oudin MJ, Prytyskach M, Kohler RH, Weissleder R, Lauffenburger DA, Miller MA. Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy. Sci Adv 2020;6:eaaz8521. [PMID: 32494745 DOI: 10.1126/sciadv.aaz8521] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
405 Stewart A, Thavasu P, de Bono JS, Banerji U. Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors. Ann Oncol 2015;26:1504-10. [PMID: 25908604 DOI: 10.1093/annonc/mdv188] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
406 Castagnino N, Maffei M, Tortolina L, Zoppoli G, Piras D, Nencioni A, Moran E, Ballestrero A, Patrone F, Parodi S. Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial. Wiley Interdiscip Rev Syst Biol Med 2016;8:314-36. [PMID: 27240214 DOI: 10.1002/wsbm.1342] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
407 Curtin JC. Novel drug discovery opportunities for colorectal cancer. Expert Opin Drug Discov. 2013;8:1153-1164. [PMID: 23768167 DOI: 10.1517/17460441.2013.807249] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
408 Nguyen LC, Naulaerts S, Bruna A, Ghislat G, Ballester PJ. Predicting Cancer Drug Response In Vivo by Learning an Optimal Feature Selection of Tumour Molecular Profiles. Biomedicines 2021;9:1319. [PMID: 34680436 DOI: 10.3390/biomedicines9101319] [Reference Citation Analysis]
409 Sale MJ, Cook SJ. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Biochem J. 2013;450:285-294. [PMID: 23234544 DOI: 10.1042/bj20121212] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
410 Schreck KC, Grossman SA, Pratilas CA. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers (Basel) 2019;11:E1262. [PMID: 31466300 DOI: 10.3390/cancers11091262] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
411 Wang J, Pollard K, Allen AN, Tomar T, Pijnenburg D, Yao Z, Rodriguez FJ, Pratilas CA. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors. Cancer Res 2020;80:5367-79. [PMID: 33032988 DOI: 10.1158/0008-5472.CAN-20-1365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
412 Berns K, Bernards R. Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist Updat 2012;15:268-75. [PMID: 23142522 DOI: 10.1016/j.drup.2012.10.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
413 Herr R, Brummer T. BRAF inhibitors in colorectal cancer: Toward a differentiation therapy? Mol Cell Oncol. 2015;2:e1002709. [PMID: 27308494 DOI: 10.1080/23723556.2014.1002709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
414 Akhave NS, Biter AB, Hong DS. Mechanisms of Resistance to KRASG12C-Targeted Therapy. Cancer Discov 2021;11:1345-52. [PMID: 33820777 DOI: 10.1158/2159-8290.CD-20-1616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
415 Solit DB, Jänne PA. Primed for resistance. Nature 2012;483:44-5. [DOI: 10.1038/483044a] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
416 Hata AN, Shaw AT. Resistance looms for KRASG12C inhibitors. Nat Med 2020;26:169-70. [PMID: 32020086 DOI: 10.1038/s41591-020-0765-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
417 Chakraborty R, Wieland CN, Comfere NI. Molecular targeted therapies in metastatic melanoma. Pharmgenomics Pers Med 2013;6:49-56. [PMID: 23843700 DOI: 10.2147/PGPM.S44800] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
418 Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther 2013;14:703-10. [PMID: 23792568 DOI: 10.4161/cbt.25191] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
419 Garbe C, Eigentler TK. Vemurafenib. Recent Results Cancer Res 2018;211:77-89. [PMID: 30069761 DOI: 10.1007/978-3-319-91442-8_6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
420 Gong K, Guo G, Beckley NA, Yang X, Zhang Y, Gerber DE, Minna JD, Burma S, Zhao D, Akbay EA, Habib AA. Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. Nat Commun 2021;12:7014. [PMID: 34853306 DOI: 10.1038/s41467-021-27276-7] [Reference Citation Analysis]
421 de Jong PR, Taniguchi K, Harris AR, Bertin S, Takahashi N, Duong J, Campos AD, Powis G, Corr M, Karin M, Raz E. ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation. Nat Commun 2016;7:11551. [PMID: 27187615 DOI: 10.1038/ncomms11551] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 7.5] [Reference Citation Analysis]
422 Jastrzebski K, Evers B, Beijersbergen RL. Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery Platform. Methods Mol Biol 2016;1470:49-73. [PMID: 27581284 DOI: 10.1007/978-1-4939-6337-9_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
423 Rad R, Cadiñanos J, Rad L, Varela I, Strong A, Kriegl L, Constantino-Casas F, Eser S, Hieber M, Seidler B, Price S, Fraga MF, Calvanese V, Hoffman G, Ponstingl H, Schneider G, Yusa K, Grove C, Schmid RM, Wang W, Vassiliou G, Kirchner T, McDermott U, Liu P, Saur D, Bradley A. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 2013;24:15-29. [PMID: 23845441 DOI: 10.1016/j.ccr.2013.05.014] [Cited by in Crossref: 129] [Cited by in F6Publishing: 116] [Article Influence: 14.3] [Reference Citation Analysis]
424 Mulero-Sánchez A, Pogacar Z, Vecchione L. Importance of genetic screens in precision oncology. ESMO Open 2019;4:e000505. [PMID: 31231569 DOI: 10.1136/esmoopen-2019-000505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
425 Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer 2015;15:302-10. [PMID: 25855404 DOI: 10.1038/nrc3918] [Cited by in Crossref: 204] [Cited by in F6Publishing: 185] [Article Influence: 29.1] [Reference Citation Analysis]
426 Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020;5:22. [PMID: 32296018 DOI: 10.1038/s41392-020-0116-z] [Cited by in Crossref: 130] [Cited by in F6Publishing: 140] [Article Influence: 65.0] [Reference Citation Analysis]
427 Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, Kesari S, Sarkaria JN, Zhao D, Habib AA. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nat Neurosci. 2017;20:1074-1084. [PMID: 28604685 DOI: 10.1038/nn.4584] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 9.2] [Reference Citation Analysis]
428 Spiegel J, Cromm PM, Zimmermann G, Grossmann TN, Waldmann H. Small-molecule modulation of Ras signaling. Nat Chem Biol 2014;10:613-22. [PMID: 24929527 DOI: 10.1038/nchembio.1560] [Cited by in Crossref: 145] [Cited by in F6Publishing: 129] [Article Influence: 18.1] [Reference Citation Analysis]
429 Corcoran RB. New therapeutic strategies for BRAF mutant colorectal cancers. J Gastrointest Oncol 2015;6:650-9. [PMID: 26697198 DOI: 10.3978/j.issn.2078-6891.2015.076] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
430 Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013;10:390-9. [PMID: 23712190 DOI: 10.1038/nrclinonc.2013.83] [Cited by in Crossref: 125] [Cited by in F6Publishing: 114] [Article Influence: 13.9] [Reference Citation Analysis]
431 Blair BG, Bardelli A, Park BH. Somatic alterations as the basis for resistance to targeted therapies. J Pathol 2014;232:244-54. [PMID: 24114654 DOI: 10.1002/path.4278] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
432 de Cuba EMV, Kwakman R, van Egmond M, Bosch LJW, Bonjer HJ, Meijer GA, te Velde EA. Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: Future possibilities for personalised treatment by use of biomarkers. Virchows Arch 2012;461:231-43. [DOI: 10.1007/s00428-012-1287-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
433 Adackapara CA, Sholl LM, Barletta JA, Hornick JL. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology. 2013;63:187-193. [PMID: 23763264 DOI: 10.1111/his.12154] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 7.3] [Reference Citation Analysis]
434 Tauriello DV, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017;11:97-119. [PMID: 28085225 DOI: 10.1002/1878-0261.12018] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 14.0] [Reference Citation Analysis]
435 Giopanou I, Pintzas A. RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies. Crit Rev Oncol Hematol 2020;146:102859. [PMID: 31927392 DOI: 10.1016/j.critrevonc.2019.102859] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
436 Conti A, Majorini MT, Elliott R, Ashworth A, Lord CJ, Cancelliere C, Bardelli A, Seneci P, Walczak H, Delia D, Lecis D. Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. Oncotarget 2015;6:10994-1008. [PMID: 26028667 DOI: 10.18632/oncotarget.3552] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
437 Gozgit JM, Chen TH, Song Y, Wardwell S, Wang F, Cai J, Li H, Edgren H, Rivera VM, Pritchard J. RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. Oncotarget 2018;9:29654-64. [PMID: 30038711 DOI: 10.18632/oncotarget.25664] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
438 Bernards R. Finding effective cancer therapies through loss of function genetic screens. Current Opinion in Genetics & Development 2014;24:23-9. [DOI: 10.1016/j.gde.2013.11.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
439 Joudeh J, Allen JE, Das A, Prabhu V, Farbaniec M, Adler J, El-Deiry WS. Novel antineoplastics targeting genetic changes in colorectal cancer. Adv Exp Med Biol. 2013;779:1-34. [PMID: 23288633 DOI: 10.1007/978-1-4614-6176-0_1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
440 Boshuizen J, Peeper DS. Rational Cancer Treatment Combinations: An Urgent Clinical Need. Molecular Cell 2020;78:1002-18. [DOI: 10.1016/j.molcel.2020.05.031] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
441 McCoach CE, Bivona TG. Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer Discov 2019;9:587-604. [PMID: 30992280 DOI: 10.1158/2159-8290.CD-18-1196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
442 Li Q, Zhu Y, Hou L, Wang J, Hu G, Fang X, Hu Y, Tao T, Wei X, Tang H, Huang B, Hu W. C23 promotes tumorigenesis via suppressing p53 activity. Oncotarget 2016;7:58274-85. [PMID: 27506938 DOI: 10.18632/oncotarget.11071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
443 Riedl JM, Hasenleithner SO, Pregartner G, Scheipner L, Posch F, Groller K, Kashofer K, Jahn SW, Bauernhofer T, Pichler M, Stöger H, Berghold A, Hoefler G, Speicher MR, Heitzer E, Gerger A. Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial. Ther Adv Med Oncol 2021;13:1758835920987658. [PMID: 33717225 DOI: 10.1177/1758835920987658] [Reference Citation Analysis]
444 Lam M, Pant S, Yap TA. Combination drug development in BRAF mutant colorectal cancer. Oncoscience 2018;5:51-3. [PMID: 29854866 DOI: 10.18632/oncoscience.399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
445 Ramroop JR, Stein MN, Drake JM. Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer. Front Oncol 2018;8:28. [PMID: 29503809 DOI: 10.3389/fonc.2018.00028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
446 Song H, Zhang J, Ning L, Zhang H, Chen D, Jiao X, Zhang K. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Med Sci Monit 2018;24:3002-10. [PMID: 29737325 DOI: 10.12659/MSM.910084] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
447 Paul JM, Toosi B, Vizeacoumar FS, Bhanumathy KK, Li Y, Gerger C, El Zawily A, Freywald T, Anderson DH, Mousseau D, Kanthan R, Zhang Z, Vizeacoumar FJ, Freywald A. Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment. Oncotarget 2016;7:50027-42. [PMID: 27418135 DOI: 10.18632/oncotarget.10569] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
448 Garay JP, Gray JW. Omics and therapy - a basis for precision medicine. Mol Oncol 2012;6:128-39. [PMID: 22445068 DOI: 10.1016/j.molonc.2012.02.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
449 Hanly EK, Bednarczyk RB, Tuli NY, Moscatello AL, Halicka HD, Li J, Geliebter J, Darzynkiewicz Z, Tiwari RK. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Oncotarget 2015;6:39702-13. [PMID: 26284586 DOI: 10.18632/oncotarget.4052] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
450 Shi T, Gao M, He M, Yue F, Zhao Y, Sun M, He K, Chen L. 5-FU preferably induces apoptosis in BRAF V600E colorectal cancer cells via downregulation of Bcl-xL. Mol Cell Biochem 2019;461:151-8. [DOI: 10.1007/s11010-019-03598-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
451 Kassouf E, Tabchi S, Tehfe M. Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis. BioDrugs 2016;30:95-104. [PMID: 26927802 DOI: 10.1007/s40259-016-0166-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
452 van Brummelen EMJ, de Boer A, Beijnen JH, Schellens JHM. BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. Oncologist. 2017;22:864-872. [PMID: 28576857 DOI: 10.1634/theoncologist.2017-0031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
453 Xu C, Qi Y, Cui Z, Yang Y, Wang J, Hu Y, Yu B, Wang F, Yang Q, Sun H. Discovery of novel elongator protein 2 inhibitors by compound library screening using surface plasmon resonance. RSC Adv 2019;9:1696-704. [DOI: 10.1039/c8ra09640f] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
454 Garcia-Murillas I, Sharpe R, Pearson A, Campbell J, Natrajan R, Ashworth A, Turner NC. An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer. Oncogene 2014;33:2478-86. [PMID: 23752180 DOI: 10.1038/onc.2013.202] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
455 Machnicki MM, Stoklosa T. BRAF--a new player in hematological neoplasms. Blood Cells Mol Dis 2014;53:77-83. [PMID: 24495477 DOI: 10.1016/j.bcmd.2014.01.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
456 Zhang G, Herlyn M. Linking SOX10 to a slow-growth resistance phenotype. Cell Res 2014;24:906-7. [PMID: 24853952 DOI: 10.1038/cr.2014.67] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
457 Nussinov R, Muratcioglu S, Tsai CJ, Jang H, Gursoy A, Keskin O. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas. Mol Cancer Res 2015;13:1265-73. [PMID: 26085527 DOI: 10.1158/1541-7786.MCR-15-0165] [Cited by in Crossref: 58] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
458 Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501:338-345. [PMID: 24048066 DOI: 10.1038/nature12625] [Cited by in Crossref: 1320] [Cited by in F6Publishing: 1151] [Article Influence: 146.7] [Reference Citation Analysis]
459 Stover EH, Feltmate C, Berkowitz RS, Lindeman NI, Matulonis UA, Konstantinopoulos PA. Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma. JCO Precis Oncol 2018;2018. [PMID: 30828692 DOI: 10.1200/PO.18.00135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
460 Pal S, Konkimalla VB, Kathawate L, Rao SS, Gejji SP, Puranik VG, Weyhermüller T, Salunke-gawali S. Targeting a chemorefractory COLO205 (BRAF V600E) cell line using substituted benzo[α]phenoxazines. RSC Adv 2015;5:82549-63. [DOI: 10.1039/c5ra14949e] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
461 Ganesh S, Shui X, Craig KP, Koser ML, Chopda GR, Cyr WA, Lai C, Dudek H, Wang W, Brown BD, Abrams MT. β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models. Mol Cancer Ther 2018;17:544-53. [PMID: 29282298 DOI: 10.1158/1535-7163.MCT-17-0605] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
462 Doebele RC, Camidge DR. Targeting ALK, ROS1, and BRAF kinases. J Thorac Oncol 2012;7:S375-6. [PMID: 23160323 DOI: 10.1097/JTO.0b013e31826df05e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
463 Caiazza F, Elliott L, Fennelly D, Sheahan K, Doherty GA, Ryan EJ. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. Biomark Med 2015;9:363-75. [PMID: 25808440 DOI: 10.2217/bmm.15.5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
464 Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 2013;19:2688-98. [PMID: 23549875 DOI: 10.1158/1078-0432.CCR-12-2556] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
465 Yu Y, Wang X, Li Q, Zhang M, Xu P, Chen Y, Yan Y, Zhang L. Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations. Oncol Lett 2018;15:635-41. [PMID: 29387237 DOI: 10.3892/ol.2017.7330] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
466 Beckman RA, Yeang CH. Nonstandard personalized medicine strategies for cancer may lead to improved patient outcomes. Per Med 2014;11:705-19. [PMID: 29764056 DOI: 10.2217/pme.14.57] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
467 Gerhards NM, Rottenberg S. New tools for old drugs: Functional genetic screens to optimize current chemotherapy. Drug Resist Updat 2018;36:30-46. [PMID: 29499836 DOI: 10.1016/j.drup.2018.01.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
468 Vakiani E, Yaeger R, Brooke S, Zhou Y, Klimstra DS, Shia J. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms. Appl Immunohistochem Mol Morphol 2015;23:438-43. [PMID: 25517872 DOI: 10.1097/PAI.0000000000000116] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
469 Klomp JE, Klomp JA, Der CJ. The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. Biochem Soc Trans 2021;49:253-67. [PMID: 33544118 DOI: 10.1042/BST20200507] [Reference Citation Analysis]
470 Carr TH, McEwen R, Dougherty B, Johnson JH, Dry JR, Lai Z, Ghazoui Z, Laing NM, Hodgson DR, Cruzalegui F, Hollingsworth SJ, Barrett JC. Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer 2016;16:319-29. [PMID: 27112209 DOI: 10.1038/nrc.2016.35] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 12.4] [Reference Citation Analysis]
471 Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M. Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. Nat Med 2015;21:741-50. [PMID: 26030178 DOI: 10.1038/nm.3863] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
472 Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015;10:S1-63. [PMID: 25535693 DOI: 10.1097/JTO.0000000000000405] [Cited by in Crossref: 95] [Cited by in F6Publishing: 44] [Article Influence: 13.6] [Reference Citation Analysis]
473 Naim N, Moukheiber S, Daou S, Kourie HR. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. Crit Rev Oncol Hematol 2021;168:103524. [PMID: 34800654 DOI: 10.1016/j.critrevonc.2021.103524] [Reference Citation Analysis]
474 Cseh B, Doma E, Baccarini M. "RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Lett 2014;588:2398-406. [PMID: 24937142 DOI: 10.1016/j.febslet.2014.06.025] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 8.4] [Reference Citation Analysis]
475 Santhosh S, Kumar P, Ramprasad V, Chaudhuri A. Evolution of targeted therapies in cancer: opportunities and challenges in the clinic. Future Oncology 2015;11:279-93. [DOI: 10.2217/fon.14.198] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
476 Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song J, Pencheva N, Mortensen JT, Foppen MG, Rozeman EA, Blank CU, Janmaat ML, Satijn D, Breij ECW, Peeper DS, Parren PWHI. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med 2018;24:203-12. [DOI: 10.1038/nm.4472] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 23.0] [Reference Citation Analysis]
477 Tarabichi M, Antoniou A, Saiselet M, Pita JM, Andry G, Dumont JE, Detours V, Maenhaut C. Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence". Cancer Metastasis Rev 2013;32:403-21. [PMID: 23615877 DOI: 10.1007/s10555-013-9431-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 3.9] [Reference Citation Analysis]
478 Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A, Andrikou K, Cascinu S, Gelsomino F. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. Int J Mol Sci. 2019;20. [PMID: 31661924 DOI: 10.3390/ijms20215369] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
479 Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat F, Paone A, Cascione L, Sumani KM, Veronese A, Fabbri M, Carasi S, Alder H, Lanza G, Gafa' R, Moyer MP, Ridgway RA, Cordero J, Nuovo GJ, Frankel WL, Rugge M, Fassan M, Groden J, Vogt PK, Karin M, Sansom OJ, Croce CM. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 2014;25:469-83. [PMID: 24735923 DOI: 10.1016/j.ccr.2014.03.006] [Cited by in Crossref: 199] [Cited by in F6Publishing: 200] [Article Influence: 24.9] [Reference Citation Analysis]
480 Dent P. Multi-kinase modulation for colon cancer therapy. Cancer Biol Ther 2013;14:877-8. [PMID: 24025253 DOI: 10.4161/cbt.26176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
481 Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, Rottenberg Y, Uziely B, Nechushtan H, Meirovitz A, Sonnenblick A, Sapir E, Edelman D, Goldberg Y, Lossos A, Rosenberg S, Fried I, Finklstein R, Pikarsky E, Goldshmidt H. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine (Baltimore) 2017;96:e6931. [PMID: 28514312 DOI: 10.1097/MD.0000000000006931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
482 Hu X, Zhang Z. Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches. Trends Genet 2016;32:127-37. [PMID: 26689126 DOI: 10.1016/j.tig.2015.11.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
483 Maleka A, Åström G, Byström P, Ullenhag GJ. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. BMC Cancer 2016;16:634. [PMID: 27520988 DOI: 10.1186/s12885-016-2657-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
484 Winkler EC, Wiemann S. Findings made in gene panel to whole genome sequencing: data, knowledge, ethics – and consequences? Expert Review of Molecular Diagnostics 2016;16:1259-70. [DOI: 10.1080/14737159.2016.1212662] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
485 Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Trusolino L, Bernards R. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep 2014;7:86-93. [PMID: 24685132 DOI: 10.1016/j.celrep.2014.02.045] [Cited by in Crossref: 199] [Cited by in F6Publishing: 179] [Article Influence: 24.9] [Reference Citation Analysis]
486 Westin JR. Busting robustness: using cancer's greatest strength to our advantage. Future Oncol 2015;11:73-7. [PMID: 24673642 DOI: 10.2217/fon.14.49] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
487 Mourragui SMC, Loog M, Vis DJ, Moore K, Manjon AG, van de Wiel MA, Reinders MJT, Wessels LFA. Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning. Proc Natl Acad Sci U S A 2021;118:e2106682118. [PMID: 34873056 DOI: 10.1073/pnas.2106682118] [Reference Citation Analysis]
488 Jiang L, Li R, Yan F, Yap TA, Yuan Y. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemp Clin Trials 2021;104:106338. [PMID: 33711459 DOI: 10.1016/j.cct.2021.106338] [Reference Citation Analysis]
489 Ajaz M, Jefferies S, Brazil L, Watts C, Chalmers A. Current and investigational drug strategies for glioblastoma. Clin Oncol (R Coll Radiol) 2014;26:419-30. [PMID: 24768122 DOI: 10.1016/j.clon.2014.03.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
490 Lombardo R, Tosi F, Nocerino A, Bencardino K, Gambi V, Ricotta R, Spina F, Siena S, Sartore-Bianchi A. The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. Front Oncol 2020;10:533. [PMID: 32457826 DOI: 10.3389/fonc.2020.00533] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
491 Konda JD, Olivero M, Musiani D, Lamba S, Di Renzo MF. Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF. Mol Oncol 2017;11:599-611. [PMID: 28182330 DOI: 10.1002/1878-0261.12042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
492 Geng R, Tan X, Zuo Z, Wu J, Pan Z, Shi W, Liu R, Yao C, Wang G, Lin J, Qiu L, Huang W, Chen S. Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells. Chin J Cancer 2017;36:63. [PMID: 28756770 DOI: 10.1186/s40880-017-0228-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
493 Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov. 2016;6:147-153. [PMID: 26644315 DOI: 10.1158/2159-8290.cd-15-1283] [Cited by in Crossref: 233] [Cited by in F6Publishing: 142] [Article Influence: 33.3] [Reference Citation Analysis]
494 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
495 Gao SP, Chang Q, Mao N, Daly LA, Vogel R, Chan T, Liu SH, Bournazou E, Schori E, Zhang H, Brewer MR, Pao W, Morris L, Ladanyi M, Arcila M, Manova-Todorova K, de Stanchina E, Norton L, Levine RL, Altan-Bonnet G, Solit D, Zinda M, Huszar D, Lyden D, Bromberg JF. JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Sci Signal 2016;9:ra33. [PMID: 27025877 DOI: 10.1126/scisignal.aac8460] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
496 Chu Y, Yuan Y. BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity. J R Stat Soc C 2017;67:723-40. [DOI: 10.1111/rssc.12255] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
497 van Geel RM, Beijnen JH, Bernards R, Schellens JH. Treatment Individualization in Colorectal Cancer. Curr Colorectal Cancer Rep 2015;11:335-44. [PMID: 26617477 DOI: 10.1007/s11888-015-0288-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
498 Ramón Y Cajal S, Segura MF, Hümmer S. Interplay Between ncRNAs and Cellular Communication: A Proposal for Understanding Cell-Specific Signaling Pathways. Front Genet 2019;10:281. [PMID: 31001323 DOI: 10.3389/fgene.2019.00281] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
499 Khoja L, Hogg D. Dabrafenib in the treatment of metastatic or unresectable melanoma. Expert Review of Anticancer Therapy 2015;15:265-76. [DOI: 10.1586/14737140.2015.1014343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
500 Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T. Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. J Neurooncol 2017;131:495-505. [PMID: 27848137 DOI: 10.1007/s11060-016-2333-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
501 Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013;13:759-71. [DOI: 10.1038/nrc3611] [Cited by in Crossref: 917] [Cited by in F6Publishing: 911] [Article Influence: 101.9] [Reference Citation Analysis]
502 Perimenis P, Galaris A, Voulgari A, Prassa M, Pintzas A. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis. BMC Cancer 2016;16:624. [PMID: 27520705 DOI: 10.1186/s12885-016-2606-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
503 Haarberg HE, Smalley KS. Resistance to Raf inhibition in cancer. Drug Discov Today Technol 2014;11:27-32. [PMID: 24847650 DOI: 10.1016/j.ddtec.2013.12.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
504 Ali SM, He J, Carson W, Stephens PJ, Fiorillo J, Lipson D, Palmer GA, Ross JS, Miller VA, Sharman J. Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib. Case Rep Oncol 2014;7:343-8. [PMID: 24987354 DOI: 10.1159/000363377] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
505 Yadav V, Chen SH, Yue YG, Buchanan S, Beckmann RP, Peng SB. Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. Pharmacol Ther 2015;149:139-49. [PMID: 25550229 DOI: 10.1016/j.pharmthera.2014.12.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
506 Eckhardt SG, Lieu C. Is Precision Medicine an Oxymoron? JAMA Oncol 2019;5:142-3. [PMID: 30419105 DOI: 10.1001/jamaoncol.2018.5099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
507 El-Khoury R, Hafliger E, Gallois C, Louafi S, Garinet S, Zaanan A, Taieb J. Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer. Eur J Cancer 2021;152:1-3. [PMID: 34058699 DOI: 10.1016/j.ejca.2021.04.027] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
508 Brunen D, García-Barchino MJ, Malani D, Jagalur Basheer N, Lieftink C, Beijersbergen RL, Murumägi A, Porkka K, Wolf M, Zwaan CM, Fornerod M, Kallioniemi O, Martínez-Climent JÁ, Bernards R. Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling. Oncotarget 2016;7:37407-19. [PMID: 27270648 DOI: 10.18632/oncotarget.9822] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
509 Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov 2016;6:594-600. [PMID: 27048246 DOI: 10.1158/2159-8290.CD-15-1192] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
510 Ursem C, Atreya CE, Van Loon K. Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointest Cancer. 2018;8:13-23. [PMID: 29628780 DOI: 10.2147/gictt.s125940] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
511 Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 2014;4:42-52. [PMID: 24163374 DOI: 10.1158/2159-8290.CD-13-0315] [Cited by in Crossref: 91] [Cited by in F6Publishing: 62] [Article Influence: 10.1] [Reference Citation Analysis]
512 Tholander B, Koliadi A, Botling J, Dahlstrand H, Von Heideman A, Ahlström H, Öberg K, Ullenhag GJ. Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma. Ups J Med Sci 2020;125:325-9. [PMID: 33043759 DOI: 10.1080/03009734.2020.1826612] [Reference Citation Analysis]
513 Hagan S, Orr MC, Doyle B. Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J 2013;4:3. [PMID: 23356214 DOI: 10.1186/1878-5085-4-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
514 Papadakis AI, Sun C, Knijnenburg TA, Xue Y, Grernrum W, Hölzel M, Nijkamp W, Wessels LF, Beijersbergen RL, Bernards R, Huang S. SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Res 2015;25:445-58. [PMID: 25656847 DOI: 10.1038/cr.2015.16] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
515 Naatz H, Manshian BB, Rios Luci C, Tsikourkitoudi V, Deligiannakis Y, Birkenstock J, Pokhrel S, Mädler L, Soenen SJ. Model‐Based Nanoengineered Pharmacokinetics of Iron‐Doped Copper Oxide for Nanomedical Applications. Angew Chem 2019;132:1844-52. [DOI: 10.1002/ange.201912312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
516 Kalamara A, Tobalina L, Saez-Rodriguez J. How to find the right drug for each patient? Advances and challenges in pharmacogenomics. Curr Opin Syst Biol 2018;10:53-62. [PMID: 31763498 DOI: 10.1016/j.coisb.2018.07.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
517 Olson OC, Joyce JA. Microenvironment-mediated resistance to anticancer therapies. Cell Res 2013;23:179-81. [PMID: 22945358 DOI: 10.1038/cr.2012.123] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
518 Liu L, Jin X, Hu CF, Zhang YP, Zhou Z, Li R, Shen CX. Amphiregulin enhances cardiac fibrosis and aggravates cardiac dysfunction in mice with experimental myocardial infarction partly through activating EGFR-dependent pathway. Basic Res Cardiol 2018;113:12. [PMID: 29349588 DOI: 10.1007/s00395-018-0669-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
519 Juan J, Muraguchi T, Iezza G, Sears RC, McMahon M. Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev 2014;28:561-75. [PMID: 24589553 DOI: 10.1101/gad.233627.113] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
520 Laprovitera N, Riefolo M, Ambrosini E, Klec C, Pichler M, Ferracin M. Cancer of Unknown Primary: Challenges and Progress in Clinical Management. Cancers (Basel) 2021;13:451. [PMID: 33504059 DOI: 10.3390/cancers13030451] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
521 Graham DM, Coyle VM, Kennedy RD, Wilson RH. Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 2016;12:141-50. [PMID: 27340376 DOI: 10.1007/s11888-016-0312-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
522 Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis 2013;34:725-38. [PMID: 23455378 DOI: 10.1093/carcin/bgt086] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
523 Ma R, Xu L, Qu X, Che X, Zhang Y, Fan Y, Li C, Guo T, Hou K, Hu X, Drew L, Shen M, Cheung T, Liu Y. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status. Br J Cancer 2018;118:1453-63. [PMID: 29755114 DOI: 10.1038/s41416-018-0086-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
524 Janku F. Tumor heterogeneity in the clinic: is it a real problem? Ther Adv Med Oncol 2014;6:43-51. [PMID: 24587830 DOI: 10.1177/1758834013517414] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
525 Palit SAL, van Dorp J, Vis D, Lieftink C, Linder S, Beijersbergen R, Bergman AM, Zwart W, van der Heijden MS. A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Sci Rep 2021;11:13683. [PMID: 34211036 DOI: 10.1038/s41598-021-93107-w] [Reference Citation Analysis]
526 Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, Rodrigues CMP, Lozano E, Mancarella S, Segatto O, Vaquero J, Marin JJG, Coulouarn C. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 2019;39 Suppl 1:43-62. [PMID: 30903728 DOI: 10.1111/liv.14102] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
527 Renovanz M, Kim EL. Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment. Front Oncol. 2014;4:142. [PMID: 24959421 DOI: 10.3389/fonc.2014.00142] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
528 Huang L, Jiang Y, Chen Y. Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway. Sci Rep 2017;7:40752. [PMID: 28102344 DOI: 10.1038/srep40752] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
529 Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw CN, Miao B, Frederick DT, Wargo JA, Flaherty KT, Jönsson G, Tsao H. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol 2015;135:1863-72. [PMID: 25789707 DOI: 10.1038/jid.2015.105] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 7.4] [Reference Citation Analysis]
530 Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 2013;3:158-67. [PMID: 23242808 DOI: 10.1158/2159-8290.CD-12-0386] [Cited by in Crossref: 231] [Cited by in F6Publishing: 157] [Article Influence: 23.1] [Reference Citation Analysis]
531 Begum R, Martin SA. Targeting Mismatch Repair defects: A novel strategy for personalized cancer treatment. DNA Repair 2016;38:135-9. [DOI: 10.1016/j.dnarep.2015.11.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
532 Huijberts SC, van Geel RM, Bernards R, Beijnen JH, Steeghs N. Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer. Future Oncol 2020;16:161-73. [PMID: 32027186 DOI: 10.2217/fon-2019-0748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
533 Cheng LC, Tan VM, Ganesan S, Drake JM. Integrating phosphoproteomics into the clinical management of prostate cancer. Clin Transl Med 2017;6:9. [PMID: 28197968 DOI: 10.1186/s40169-017-0138-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
534 Hertzman Johansson C, Egyhazi Brage S. BRAF inhibitors in cancer therapy. Pharmacol Ther. 2014;142:176-182. [PMID: 24325952 DOI: 10.1016/j.pharmthera.2013.11.011] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
535 Sammarco G, Gallo G, Vescio G, Picciariello A, De Paola G, Trompetto M, Currò G, Ammendola M. Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. J Clin Med 2020;9:E2852. [PMID: 32899322 DOI: 10.3390/jcm9092852] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
536 Kocoglu H, Velibeyoglu FM, Karaca M, Tural D. Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. World J Gastrointest Oncol 2016; 8(1): 1-7 [PMID: 26798432 DOI: 10.4251/wjgo.v8.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
537 Kondo T. Current status and perspectives of patient-derived rare cancer models. Human Cell 2020;33:919-29. [DOI: 10.1007/s13577-020-00391-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
538 Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16:281-298. [PMID: 25907612 DOI: 10.1038/nrm3979] [Cited by in Crossref: 312] [Cited by in F6Publishing: 285] [Article Influence: 44.6] [Reference Citation Analysis]
539 Zaman A, Wu W, Bivona TG. Targeting Oncogenic BRAF: Past, Present, and Future. Cancers (Basel). 2019;11. [PMID: 31426419 DOI: 10.3390/cancers11081197] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
540 Siu LL, Conley BA, Boerner S, LoRusso PM. Next-Generation Sequencing to Guide Clinical Trials. Clin Cancer Res 2015;21:4536-44. [PMID: 26473189 DOI: 10.1158/1078-0432.CCR-14-3215] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
541 Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. Oncologist 2016;21:1315-25. [PMID: 27566247 DOI: 10.1634/theoncologist.2016-0049] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
542 Lavacchi D, Roviello G, D'Angelo A. Tumor-Agnostic Treatment for Cancer: When How is Better than Where. Clin Drug Investig 2020;40:519-27. [PMID: 32307639 DOI: 10.1007/s40261-020-00915-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
543 Liu J, Tang L, Yi J, Li G, Lu Y, Xu Y, Zhao S, Mao R, Li X, Ren L, Wang K. Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer. BMC Gastroenterol 2019;19:173. [PMID: 31690257 DOI: 10.1186/s12876-019-1086-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
544 Olivier T, Fernandez E, Labidi-Galy I, Dietrich PY, Rodriguez-Bravo V, Baciarello G, Fizazi K, Patrikidou A. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? Cancer Treat Rev 2021;97:102204. [PMID: 33866225 DOI: 10.1016/j.ctrv.2021.102204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
545 Selbo PK, Bostad M, Olsen CE, Edwards VT, Høgset A, Weyergang A, Berg K. Photochemical internalisation, a minimally invasive strategy for light-controlled endosomal escape of cancer stem cell-targeting therapeutics. Photochem Photobiol Sci 2015;14:1433-50. [DOI: 10.1039/c5pp00027k] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
546 Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34163045 DOI: 10.1038/s41575-021-00465-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
547 Bleeker FE, Lamba S, Zanon C, Molenaar RJ, Hulsebos TJ, Troost D, van Tilborg AA, Vandertop WP, Leenstra S, van Noorden CJ, Bardelli A. Mutational profiling of kinases in glioblastoma. BMC Cancer 2014;14:718. [PMID: 25256166 DOI: 10.1186/1471-2407-14-718] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
548 Lv Y, Wang X, Ren Y, Fu X, Li T, Jiang Q. Construction of an immune-related signature with prognostic value for colon cancer. PeerJ 2021;9:e10812. [PMID: 33996273 DOI: 10.7717/peerj.10812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
549 Lee CI, Liao CB, Chen CS, Cheng FY, Chung YH, Wang YC, Ciou SY, Hsueh WY, Lo TH, Huang GR, Huang HY, Tsai CS, Lu YJ, Chuang SH, Huang JJ. Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines. Bioorg Chem 2021;109:104715. [PMID: 33647741 DOI: 10.1016/j.bioorg.2021.104715] [Reference Citation Analysis]
550 Zhou ZL, Deng JF, Li YJ, Chang Y, Cheng HM. Determination of a novel B-Raf(V600E) and EGFR dual inhibitor in rat plasma by HPLC-MS/MS and its application in a pharmacokinetic study. J Pharm Biomed Anal 2016;129:142-7. [PMID: 27423011 DOI: 10.1016/j.jpba.2016.06.049] [Reference Citation Analysis]
551 Mazumder A, Cerella C, Diederich M. Natural scaffolds in anticancer therapy and precision medicine. Biotechnol Adv 2018;36:1563-85. [PMID: 29729870 DOI: 10.1016/j.biotechadv.2018.04.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
552 Wilkes G, Hartshorn K. Clinical update: colon, rectal, and anal cancers. Semin Oncol Nurs. 2012;28:e1-22. [PMID: 23107187 DOI: 10.1016/j.soncn.2012.09.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
553 Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 2017;28:34-43. [PMID: 28177494 DOI: 10.1093/annonc/mdw413] [Cited by in Crossref: 130] [Cited by in F6Publishing: 110] [Article Influence: 32.5] [Reference Citation Analysis]
554 Bosdriesz E, Prahallad A, Klinger B, Sieber A, Bosma A, Bernards R, Blüthgen N, Wessels LFA. Comparative Network Reconstruction using mixed integer programming. Bioinformatics 2018;34:i997-i1004. [PMID: 30423075 DOI: 10.1093/bioinformatics/bty616] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
555 Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013;19:3533-3544. [PMID: 23674493 DOI: 10.1158/1078-0432.ccr-12-3815] [Cited by in Crossref: 94] [Cited by in F6Publishing: 59] [Article Influence: 10.4] [Reference Citation Analysis]
556 Temraz S, Alameddine R, Shamseddine A. B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches. Current Opinion in Oncology 2015;27:276-81. [DOI: 10.1097/cco.0000000000000184] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
557 Martin-liberal J, Larkin J. New RAF kinase inhibitors in cancer therapy. Expert Opinion on Pharmacotherapy 2014;15:1235-45. [DOI: 10.1517/14656566.2014.911286] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
558 Klauschen F, Andreeff M, Keilholz U, Dietel M, Stenzinger A. The combinatorial complexity of cancer precision medicine. Oncoscience 2014;1:504-9. [PMID: 25594052 DOI: 10.18632/oncoscience.66] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
559 Solary E. [A reductionnist approach of cancer]. Med Sci (Paris) 2014;30:683-7. [PMID: 25014462 DOI: 10.1051/medsci/20143006021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
560 Tsai YT, Lozanski G, Lehman A, Sass EJ, Hertlein E, Salunke SB, Chen CS, Grever MR, Byrd JC, Lucas DM. BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. Leuk Res 2015:S0145-2126(15)30371-4. [PMID: 26350141 DOI: 10.1016/j.leukres.2015.08.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
561 Kelderman S, Schumacher TN, Haanen JB. Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol 2014;8:1132-9. [PMID: 25106088 DOI: 10.1016/j.molonc.2014.07.011] [Cited by in Crossref: 113] [Cited by in F6Publishing: 96] [Article Influence: 14.1] [Reference Citation Analysis]
562 Servant N, Roméjon J, Gestraud P, La Rosa P, Lucotte G, Lair S, Bernard V, Zeitouni B, Coffin F, Jules-Clément G, Yvon F, Lermine A, Poullet P, Liva S, Pook S, Popova T, Barette C, Prud'homme F, Dick JG, Kamal M, Le Tourneau C, Barillot E, Hupé P. Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial. Front Genet 2014;5:152. [PMID: 24910641 DOI: 10.3389/fgene.2014.00152] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
563 Siraj AK, Bu R, Prabhakaran S, Bavi P, Beg S, Al Hazmi M, Al-Rasheed M, Alobaisi K, Al-Dayel F, AlManea H, Al-Sanea N, Uddin S, Al-Kuraya KS. A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Mol Cancer 2014;13:168. [PMID: 25005754 DOI: 10.1186/1476-4598-13-168] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
564 García-alfonso P, García-foncillas J, Salazar R, Pérez-segura P, García-carbonero R, Musulén-palet E, Cuatrecasas M, Landolfi S, Ramón y Cajal S, Navarro S. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2015;17:264-73. [DOI: 10.1007/s12094-014-1252-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
565 Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13:928-942. [PMID: 25435214 DOI: 10.1038/nrd4281] [Cited by in Crossref: 613] [Cited by in F6Publishing: 571] [Article Influence: 87.6] [Reference Citation Analysis]
566 Lavallée VP, Baccelli I, Krosl J, Wilhelm B, Barabé F, Gendron P, Boucher G, Lemieux S, Marinier A, Meloche S, Hébert J, Sauvageau G. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat Genet 2015;47:1030-7. [PMID: 26237430 DOI: 10.1038/ng.3371] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 13.4] [Reference Citation Analysis]
567 Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Mol Cancer Ther 2016;15:3015-27. [PMID: 27765849 DOI: 10.1158/1535-7163.MCT-16-0017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
568 Yang J, Xu WW, Hong P, Ye F, Huang XH, Hu HF, Zhang QH, Yan X, Li B, He QY. Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction. Cancer Lett 2019;451:79-91. [PMID: 30872078 DOI: 10.1016/j.canlet.2019.02.050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
569 Kwong LN, Heffernan TP, Chin L. A systems biology approach to personalizing therapeutic combinations. Cancer Discov 2013;3:1339-44. [PMID: 24327696 DOI: 10.1158/2159-8290.CD-13-0394] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
570 Kochi M, Hinoi T, Niitsu H, Miguchi M, Saito Y, Sada H, Sentani K, Sakamoto N, Oue N, Tashiro H, Sotomaru Y, Yasui W, Ohdan H. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer. Cancer Sci 2020;111:3540-9. [PMID: 32629543 DOI: 10.1111/cas.14558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
571 Uda Y, Goto Y, Oda S, Kohchi T, Matsuda M, Aoki K. Efficient synthesis of phycocyanobilin in mammalian cells for optogenetic control of cell signaling. Proc Natl Acad Sci U S A 2017;114:11962-7. [PMID: 29078307 DOI: 10.1073/pnas.1707190114] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 9.4] [Reference Citation Analysis]
572 Trullas A, Delgado J, Koenig J, Fuerstenau U, Dedorath J, Hausmann S, Stock T, Enzmann H, Pignatti F. The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy. ESMO Open 2021;6:100031. [PMID: 33422765 DOI: 10.1016/j.esmoop.2020.100031] [Reference Citation Analysis]
573 Bivona TG, Doebele RC. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat Med 2016;22:472-8. [PMID: 27149220 DOI: 10.1038/nm.4091] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 16.8] [Reference Citation Analysis]
574 Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer 2021;9:e002459. [PMID: 34215688 DOI: 10.1136/jitc-2021-002459] [Reference Citation Analysis]
575 Dittrich C. Basket trials: From tumour gnostic to tumour agnostic drug development. Cancer Treatment Reviews 2020;90:102082. [DOI: 10.1016/j.ctrv.2020.102082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
576 Ma P, Fu Y, Chen M, Jing Y, Wu J, Li K, Shen Y, Gao JX, Wang M, Zhao X, Zhuang G. Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway. Theranostics 2016;6:1232-43. [PMID: 27279914 DOI: 10.7150/thno.14409] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
577 Temraz S, Mukherji D, Alameddine R, Shamseddine A. Methods of overcoming treatment resistance in colorectal cancer. Crit Rev Oncol Hematol 2014;89:217-30. [PMID: 24075059 DOI: 10.1016/j.critrevonc.2013.08.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
578 Lackner MR, Wilson TR, Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol. 2012;8:999-1014. [PMID: 22894672 DOI: 10.2217/fon.12.86] [Cited by in Crossref: 118] [Cited by in F6Publishing: 101] [Article Influence: 11.8] [Reference Citation Analysis]
579 Sandhu J, Lavingia V, Fakih M. Systemic treatment for metastatic colorectal cancer in the era of precision medicine. J Surg Oncol 2019;119:564-82. [PMID: 30802315 DOI: 10.1002/jso.25421] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
580 Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017;6. [PMID: 28891793 DOI: 10.7554/elife.27861] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 16.0] [Reference Citation Analysis]
581 Mondaca S, Yaeger R. Colorectal cancer genomics and designing rational trials. Ann Transl Med 2018;6:159. [PMID: 29911107 DOI: 10.21037/atm.2018.03.27] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
582 Fedorenko IV, Fang B, Munko AC, Gibney GT, Koomen JM, Smalley KS. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics 2015;15:327-39. [PMID: 25339196 DOI: 10.1002/pmic.201400200] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
583 Kohno T. Implementation of "clinical sequencing" in cancer genome medicine in Japan. Cancer Sci 2018;109:507-12. [PMID: 29285848 DOI: 10.1111/cas.13486] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
584 McQuade J, Davies MA. Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Manag 2015;2:241-54. [PMID: 26594316 DOI: 10.2217/mmt.15.18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
585 Haydn JM, Hufnagel A, Grimm J, Maurus K, Schartl M, Meierjohann S. The MAPK pathway as an apoptosis enhancer in melanoma. Oncotarget 2014;5:5040-53. [PMID: 24970815 DOI: 10.18632/oncotarget.2079] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
586 Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012;26:1131-55. [PMID: 22661227 DOI: 10.1101/gad.191999.112] [Cited by in Crossref: 326] [Cited by in F6Publishing: 293] [Article Influence: 32.6] [Reference Citation Analysis]
587 Zhen Y, Thomas-schoemann A, Sakji L, Boudou-rouquette P, Dupin N, Mortier L, Vidal M, Goldwasser F, Blanchet B. An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. Journal of Chromatography B 2013;928:93-7. [DOI: 10.1016/j.jchromb.2013.03.017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
588 Kim B, Wang S, Lee JM, Jeong Y, Ahn T, Son DS, Park HW, Yoo HS, Song YJ, Lee E, Oh YM, Lee SB, Choi J, Murray JC, Zhou Y, Song PH, Kim KA, Weiner LM. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 2015;34:1083-93. [PMID: 24662823 DOI: 10.1038/onc.2014.51] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
589 Martini G, Dienstmann R, Ros J, Baraibar I, Cuadra-Urteaga JL, Salva F, Ciardiello D, Mulet N, Argiles G, Tabernero J, Elez E. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Ther Adv Med Oncol 2020;12:1758835920936089. [PMID: 32782486 DOI: 10.1177/1758835920936089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
590 Gross A, Niemetz-Rahn A, Nonnenmacher A, Tucholski J, Keilholz U, Fusi A. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway. Target Oncol 2015;10:77-84. [PMID: 24824730 DOI: 10.1007/s11523-014-0318-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
591 Hanna DL, Lenz HJ. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Rev Clin Pharmacol 2016;9:1091-108. [PMID: 27031164 DOI: 10.1586/17512433.2016.1172961] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
592 Picco G, Chen ED, Alonso LG, Behan FM, Gonçalves E, Bignell G, Matchan A, Fu B, Banerjee R, Anderson E, Butler A, Benes CH, McDermott U, Dow D, Iorio F, Stronach E, Yang F, Yusa K, Saez-Rodriguez J, Garnett MJ. Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. Nat Commun 2019;10:2198. [PMID: 31097696 DOI: 10.1038/s41467-019-09940-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 15.3] [Reference Citation Analysis]
593 [DOI: 10.1101/070490] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
594 van Doeselaar S, Burgering BMT. FOXOs Maintaining the Equilibrium for Better or for Worse. Curr Top Dev Biol 2018;127:49-103. [PMID: 29433740 DOI: 10.1016/bs.ctdb.2017.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
595 Malapelle U, Passiglia F, Cremolini C, Reale ML, Pepe F, Pisapia P, Avallone A, Cortinovis D, De Stefano A, Fassan M, Fontanini G, Galetta D, Lauricella C, Listì A, Loupakis F, Pagni F, Pietrantonio F, Pilotto S, Righi L, Bianchi AS, Parra HS, Tiseo M, Verzè M, Troncone G, Novello S. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. Eur J Cancer 2021;146:74-83. [PMID: 33588147 DOI: 10.1016/j.ejca.2021.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
596 Tiacci E, Pettirossi V, Schiavoni G, Falini B. Genomics of Hairy Cell Leukemia. J Clin Oncol 2017;35:1002-10. [PMID: 28297625 DOI: 10.1200/JCO.2016.71.1556] [Cited by in Crossref: 33] [Cited by in F6Publishing: 16] [Article Influence: 6.6] [Reference Citation Analysis]
597 Ren Z, Liu J, Yao L, Li J, Qi Z, Li B. Glutamate receptor ionotropic, kainate 1 serves as a novel tumor suppressor of colorectal carcinoma and predicts clinical prognosis. Exp Ther Med 2020;20:167. [PMID: 33093905 DOI: 10.3892/etm.2020.9296] [Reference Citation Analysis]
598 Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Dummer R, Flaherty KT, Ronai ZA. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Rep 2015;11:1458-73. [PMID: 26027934 DOI: 10.1016/j.celrep.2015.04.049] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
599 Yanagihara K, Kubo T, Mihara K, Kuwata T, Ochiai A, Seyama T, Yokozaki H. Establishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma. Oncotarget 2018;9:36503-14. [PMID: 30559933 DOI: 10.18632/oncotarget.26367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
600 Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R. A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell 2016;165:317-30. [PMID: 27058664 DOI: 10.1016/j.cell.2016.02.059] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
601 Hudson AM, Wirth C, Stephenson NL, Fawdar S, Brognard J, Miller CJ. Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges. Pharmacogenomics 2015;16:1149-60. [DOI: 10.2217/pgs.15.60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
602 Borovski T, Vellinga TT, Laoukili J, Santo EE, Fatrai S, van Schelven S, Verheem A, Marvin DL, Ubink I, Borel Rinkes IHM, Kranenburg O. Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer. Gut 2017;66:1106-15. [PMID: 27670374 DOI: 10.1136/gutjnl-2016-311547] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
603 Thomopoulou K, Tzardi M, Mavroudis D, Souglakos I. A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update. Case Rep Oncol Med 2019;2019:4767019. [PMID: 30911424 DOI: 10.1155/2019/4767019] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
604 Matos AI, Carreira B, Peres C, Moura LI, Conniot J, Fourniols T, Scomparin A, Martínez-barriocanal Á, Arango D, Conde JP, Préat V, Satchi-fainaro R, Florindo HF. Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. Journal of Controlled Release 2019;307:108-38. [DOI: 10.1016/j.jconrel.2019.06.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
605 Nakamura Y, Hattori N, Iida N, Yamashita S, Mori A, Kimura K, Yoshino T, Ushijima T. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF -mutant colon cancer cells via repression of MAPK signaling pathway. Cancer Letters 2017;402:100-9. [DOI: 10.1016/j.canlet.2017.05.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
606 Tian W, Ding W, Kim S, Xu X, Pan M, Chen S. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis. Pancreatology. 2013;13:415-422. [PMID: 23890141 DOI: 10.1016/j.pan.2013.04.195] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
607 Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, Fellowes A, Semple T, Fox S, Byron K, Kowalczyk A, Thomas D, Schofield P, Bowtell DD. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol 2013;231:413-23. [PMID: 24037760 DOI: 10.1002/path.4251] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 8.5] [Reference Citation Analysis]
608 Vilar E, Tabernero J. Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov 2013;3:502-11. [PMID: 23454900 DOI: 10.1158/2159-8290.CD-12-0471] [Cited by in Crossref: 64] [Cited by in F6Publishing: 36] [Article Influence: 7.1] [Reference Citation Analysis]
609 Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, Samallin E, Boige V, Malka D, Gelli M. Molecular targeted therapy of BRAF-mutant colorectal cancer. Ther Adv Med Oncol. 2019;11:1758835919856494. [PMID: 31244912 DOI: 10.1177/1758835919856494] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
610 Burge M, Price T, Karapetis CS. First-line therapy for metastatic colorectal cancer: Current perspectives and future directions. Asia Pac J Clin Oncol 2019;15 Suppl 1:3-14. [PMID: 30758881 DOI: 10.1111/ajco.13119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
611 Yeoh Y, Low TY, Abu N, Lee PY. Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. PeerJ 2021;9:e12338. [PMID: 34733591 DOI: 10.7717/peerj.12338] [Reference Citation Analysis]
612 Kitazawa M, Miyagawa Y, Koyama M, Nakamura S, Hondo N, Miyazaki S, Muranaka F, Tokumaru S, Yamamoto Y, Ehara T, Kuroiwa M, Tanaka H, Komatsu D, Takeoka M, Soejima Y. Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG-510, a novel KRAS G12C selective inhibitor, on colon cancer cells is markedly enhanced by the combined inhibition of MEK and BCL-XL. Mol Clin Oncol 2021;15:148. [PMID: 34094546 DOI: 10.3892/mco.2021.2310] [Reference Citation Analysis]
613 Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology 2013;62:367-86. [DOI: 10.1111/his.12055] [Cited by in Crossref: 275] [Cited by in F6Publishing: 250] [Article Influence: 30.6] [Reference Citation Analysis]
614 Watanabe Y, Shido K, Niihori T, Niizuma H, Katata Y, Iizuka C, Oba D, Moriya K, Saito-nanjo Y, Onuma M, Rikiishi T, Sasahara Y, Watanabe M, Aiba S, Saito R, Sonoda Y, Tominaga T, Aoki Y, Kure S. Somatic BRAF c.1799T>A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities. Am J Med Genet 2016;170:189-94. [DOI: 10.1002/ajmg.a.37376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
615 Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013;3:520-33. [PMID: 23365119 DOI: 10.1158/2159-8290.CD-12-0531] [Cited by in Crossref: 236] [Cited by in F6Publishing: 174] [Article Influence: 26.2] [Reference Citation Analysis]
616 Jebaraj BM, Kienle D, Bühler A, Winkler D, Döhner H, Stilgenbauer S, Zenz T. BRAF mutations in chronic lymphocytic leukemia. Leuk Lymphoma 2013;54:1177-82. [PMID: 23088640 DOI: 10.3109/10428194.2012.742525] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
617 Liu Q, Bai X, Li H, Zhang Y, Zhao Y, Zhang X, Ye L. The oncoprotein HBXIP upregulates Lin28B via activating TF II D to promote proliferation of breast cancer cells: HBXIP contributes to carcinogenesis via Lin28B. Int J Cancer 2013;133:1310-22. [DOI: 10.1002/ijc.28154] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
618 Stratikopoulos EE, Dendy M, Szabolcs M, Khaykin AJ, Lefebvre C, Zhou MM, Parsons R. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell 2015;27:837-51. [PMID: 26058079 DOI: 10.1016/j.ccell.2015.05.006] [Cited by in Crossref: 146] [Cited by in F6Publishing: 132] [Article Influence: 20.9] [Reference Citation Analysis]
619 Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. Oncogene 2018;37:821-32. [PMID: 29059158 DOI: 10.1038/onc.2017.384] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
620 Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679-92. [PMID: 22781697 DOI: 10.1038/nbt.2284] [Cited by in Crossref: 629] [Cited by in F6Publishing: 530] [Article Influence: 62.9] [Reference Citation Analysis]
621 Sun HJ, Chen J, Ni B, Yang X, Wu YZ. Recent advances and current issues in single-cell sequencing of tumors. Cancer Lett 2015;365:1-10. [PMID: 26003306 DOI: 10.1016/j.canlet.2015.04.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
622 Gelfo V, Pontis F, Mazzeschi M, Sgarzi M, Mazzarini M, Solmi R, D'Uva G, Lauriola M. Glucocorticoid Receptor Modulates EGFR Feedback upon Acquisition of Resistance to Monoclonal Antibodies. J Clin Med 2019;8:E600. [PMID: 31052457 DOI: 10.3390/jcm8050600] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
623 Klauschen F, Heim D, Stenzinger A. Histological tumor typing in the age of molecular profiling. Pathology - Research and Practice 2015;211:897-900. [DOI: 10.1016/j.prp.2015.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
624 Liu Y, Fei T, Zheng X, Brown M, Zhang P, Liu XS, Wang H. An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine. Sci Rep 2016;6:22120. [PMID: 26916442 DOI: 10.1038/srep22120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
625 Nobili S, Galletta A, Brugia M, Tassi R, Petreni P, Landini I, Mini E. Emerging drugs in refractory colorectal cancer. Future Medicinal Chemistry 2015;7:1491-501. [DOI: 10.4155/fmc.15.85] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
626 Rahman MA, Salajegheh A, Smith RA, Lam AK. Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas. Endocrine 2016;54:129-38. [PMID: 27179656 DOI: 10.1007/s12020-016-0985-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
627 Gatalica Z, Millis SZ, Vranic S, Bender R, Basu GD, Voss A, Von Hoff DD. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget 2014;5:12440-7. [PMID: 25415047 DOI: 10.18632/oncotarget.2574] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
628 Wang C, Jin H, Gao D, Lieftink C, Evers B, Jin G, Xue Z, Wang L, Beijersbergen RL, Qin W, Bernards R. Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. J Hepatol 2018;69:1057-65. [PMID: 30030148 DOI: 10.1016/j.jhep.2018.07.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
629 Venkatesan S, Lamfers ML, Dirven CM, Leenstra S. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma. CNS Oncol 2016;5:77-90. [PMID: 26986934 DOI: 10.2217/cns-2015-0005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
630 Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 2013;3:534-47. [PMID: 23533263 DOI: 10.1158/2159-8290.CD-12-0502] [Cited by in Crossref: 88] [Cited by in F6Publishing: 59] [Article Influence: 9.8] [Reference Citation Analysis]
631 Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, Coffey B, Fu T, Zwiebel JA, Little RF, Marinucci D, Catalano R, Magnan R, Kibbe W, Weil C, Tricoli JV, Alexander B, Kumar S, Schwartz GK, Meric-Bernstam F, Lih CJ, McCaskill-Stevens W, Caimi P, Takebe N, Datta V, Arteaga CL, Abrams JS, Comis R, O'Dwyer PJ, Conley BA; NCI-MATCH Team. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst 2020;112:1021-9. [PMID: 31922567 DOI: 10.1093/jnci/djz245] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 36.0] [Reference Citation Analysis]
632 Rocca A, Kholodenko BN. Can Systems Biology Advance Clinical Precision Oncology? Cancers (Basel) 2021;13:6312. [PMID: 34944932 DOI: 10.3390/cancers13246312] [Reference Citation Analysis]
633 Gong K, Guo G, Panchani N, Bender ME, Gerber DE, Minna JD, Fattah F, Gao B, Peyton M, Kernstine K, Mukherjee B, Burma S, Chiang CM, Zhang S, Sathe AA, Xing C, Dao KH, Zhao D, Akbay EA, Habib AA. EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nat Cancer 2020;1:394-409. [PMID: 33269343 DOI: 10.1038/s43018-020-0048-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
634 Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T. Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol 2016; 22(25): 5668-5677 [PMID: 27433082 DOI: 10.3748/wjg.v22.i25.5668] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
635 Verlingue L, Alt M, Kamal M, Sablin MP, Zoubir M, Bousetta N, Pierga JY, Servant N, Paoletti X, Le Tourneau C. Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials. Per Med 2014;11:545-58. [PMID: 29758779 DOI: 10.2217/pme.14.30] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
636 Herr R, Halbach S, Heizmann M, Busch H, Boerries M, Brummer T. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene 2018;37:1576-93. [PMID: 29326440 DOI: 10.1038/s41388-017-0063-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
637 Diehl P, Tedesco D, Chenchik A. Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions. Drug Discov Today Technol 2014;11:11-8. [PMID: 24847648 DOI: 10.1016/j.ddtec.2013.12.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
638 Ding J, McConechy MK, Horlings HM, Ha G, Chun Chan F, Funnell T, Mullaly SC, Reimand J, Bashashati A, Bader GD, Huntsman D, Aparicio S, Condon A, Shah SP. Systematic analysis of somatic mutations impacting gene expression in 12 tumour types. Nat Commun 2015;6:8554. [PMID: 26436532 DOI: 10.1038/ncomms9554] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]
639 Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A 2014;164A:563-78. [PMID: 24443315 DOI: 10.1002/ajmg.a.36312] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
640 Sahasrabudhe NM, Lenos K, van der Horst JC, Rodríguez E, van Vliet SJ. Oncogenic BRAFV600E drives expression of MGL ligands in the colorectal cancer cell line HT29 through N-acetylgalactosamine-transferase 3. Biol Chem 2018;399:649-59. [PMID: 29894293 DOI: 10.1515/hsz-2018-0120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
641 Seghers AK, Cuyle PJ, Van Cutsem E. Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review. Target Oncol 2020;15:407-10. [PMID: 32495162 DOI: 10.1007/s11523-020-00727-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
642 Beckman RA, Antonijevic Z, Kalamegham R, Chen C. Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker. Clin Pharmacol Ther 2016;100:617-25. [PMID: 27509351 DOI: 10.1002/cpt.446] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 5.7] [Reference Citation Analysis]
643 Little AS, Smith PD, Cook SJ. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 2013;32:1207-15. [PMID: 22562245 DOI: 10.1038/onc.2012.160] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
644 Iskit S, Lieftink C, Halonen P, Shahrabi A, Possik PA, Beijersbergen RL, Peeper DS. Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer. Oncotarget 2016;7:42859-72. [PMID: 27374095 DOI: 10.18632/oncotarget.10230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
645 Hoang VT, Nyswaner K, Torres-Ayuso P, Brognard J. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells. J Biol Chem 2020;295:8470-9. [PMID: 32358059 DOI: 10.1074/jbc.RA119.012365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
646 Schmoll H, Arnold D, de Gramont A, Ducreux M, Grothey A, O’dwyer PJ, Van Cutsem E, Hermann F, Bosanac I, Bendahmane B, Mancao C, Tabernero J. MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. J Cancer Res Clin Oncol 2018;144:1197-204. [DOI: 10.1007/s00432-018-2632-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
647 Lou E. The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy. Ann Transl Med 2018;6:168. [PMID: 29911116 DOI: 10.21037/atm.2018.03.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
648 Ramón Y Cajal S, Hümmer S, Peg V, Guiu XM, De Torres I, Castellvi J, Martinez-Saez E, Hernandez-Losa J. Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics. Histopathology 2019;75:4-19. [PMID: 30667539 DOI: 10.1111/his.13828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
649 Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C, Laurent-Puig P. The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. Drugs 2019;79:1375-94. [PMID: 31347092 DOI: 10.1007/s40265-019-01165-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
650 McDonald OG, Maitra A, Hruban RH. Human correlates of provocative questions in pancreatic pathology. Adv Anat Pathol 2012;19:351-62. [PMID: 23060061 DOI: 10.1097/PAP.0b013e318273f998] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
651 Lumish MA, Cercek A. Immunotherapy for the treatment of colorectal cancer. J Surg Oncol 2021;123:760-74. [PMID: 33595891 DOI: 10.1002/jso.26357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
652 Ogilvie LA, Wierling C, Kessler T, Lehrach H, Lange BM. Predictive Modeling of Drug Treatment in the Area of Personalized Medicine. Cancer Inform 2015;14:95-103. [PMID: 26692759 DOI: 10.4137/CIN.S1933] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
653 Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A 2014;111:E748-57. [PMID: 24550319 DOI: 10.1073/pnas.1320956111] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 8.8] [Reference Citation Analysis]
654 Fakih M. Targeting mechanisms of resistance to anti-EGF receptor therapy in KRAS wild-type colorectal cancer: the path to more personalized medicine. Future Oncology 2013;9:551-60. [DOI: 10.2217/fon.12.204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
655 Korphaisarn K, Kopetz S. BRAF-Directed Therapy in Metastatic Colorectal Cancer. Cancer J 2016;22:175-8. [PMID: 27341594 DOI: 10.1097/PPO.0000000000000189] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 4.6] [Reference Citation Analysis]
656 Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF inhibitors: experience in thyroid cancer and general review of toxicity. Horm Cancer 2015;6:21-36. [PMID: 25467940 DOI: 10.1007/s12672-014-0207-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
657 Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nat Med 2017;23:929-37. [PMID: 28714990 DOI: 10.1038/nm.4369] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 17.2] [Reference Citation Analysis]
658 Prawira A, Pugh T, Stockley T, Siu L. Data resources for the identification and interpretation of actionable mutations by clinicians. Annals of Oncology 2017;28:946-57. [DOI: 10.1093/annonc/mdx023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
659 Chylek LA, Harris LA, Tung CS, Faeder JR, Lopez CF, Hlavacek WS. Rule-based modeling: a computational approach for studying biomolecular site dynamics in cell signaling systems. Wiley Interdiscip Rev Syst Biol Med. 2014;6:13-36. [PMID: 24123887 DOI: 10.1002/wsbm.1245] [Cited by in Crossref: 72] [Cited by in F6Publishing: 56] [Article Influence: 8.0] [Reference Citation Analysis]
660 Lawler M, Kaplan R, Wilson RH, Maughan T; S-CORT Consortium. Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine. Oncologist 2015;20:849-51. [PMID: 26070918 DOI: 10.1634/theoncologist.2015-0014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
661 Thiel A, Ristimäki A. Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Front Oncol 2013;3:281. [PMID: 24298448 DOI: 10.3389/fonc.2013.00281] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
662 Jin Z, Hubbard JM. Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond. Curr Oncol 2019;26:S33-42. [PMID: 31819708 DOI: 10.3747/co.26.5589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
663 Gautron A, Bachelot L, Aubry M, Leclerc D, Quéméner AM, Corre S, Rambow F, Paris A, Tardif N, Leclair HM, Marin-Bejar O, Coulouarn C, Marine JC, Galibert MD, Gilot D. CRISPR screens identify tumor-promoting genes conferring melanoma cell plasticity and resistance. EMBO Mol Med 2021;13:e13466. [PMID: 33724679 DOI: 10.15252/emmm.202013466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
664 Traynard P, Tobalina L, Eduati F, Calzone L, Saez-Rodriguez J. Logic Modeling in Quantitative Systems Pharmacology. CPT Pharmacometrics Syst Pharmacol 2017;6:499-511. [PMID: 28681552 DOI: 10.1002/psp4.12225] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
665 Dietrich S, Andrulis M, Zenz T. [Hairy cell leukemia]. Internist (Berl) 2015;56:381-90. [PMID: 25787322 DOI: 10.1007/s00108-014-3599-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
666 Sun C, Bernards R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci 2014;39:465-74. [PMID: 25239057 DOI: 10.1016/j.tibs.2014.08.010] [Cited by in Crossref: 96] [Cited by in F6Publishing: 81] [Article Influence: 12.0] [Reference Citation Analysis]
667 Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: A systematic review and meta-analysis. PLoS One. 2012;7:e47054. [PMID: 23056577 DOI: 10.1371/journal.pone.0047054] [Cited by in Crossref: 134] [Cited by in F6Publishing: 134] [Article Influence: 13.4] [Reference Citation Analysis]
668 Billing O, Holmgren Y, Nosek D, Hedman H, Hemmingsson O. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance. Oncogene 2021;40:3707-18. [PMID: 33947959 DOI: 10.1038/s41388-021-01808-3] [Reference Citation Analysis]
669 Decker B, Parker HG, Dhawan D, Kwon EM, Karlins E, Davis BW, Ramos-Vara JA, Bonney PL, McNiel EA, Knapp DW, Ostrander EA. Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test. Mol Cancer Res 2015;13:993-1002. [PMID: 25767210 DOI: 10.1158/1541-7786.MCR-14-0689] [Cited by in Crossref: 68] [Cited by in F6Publishing: 43] [Article Influence: 9.7] [Reference Citation Analysis]
670 Naatz H, Manshian BB, Rios Luci C, Tsikourkitoudi V, Deligiannakis Y, Birkenstock J, Pokhrel S, Mädler L, Soenen SJ. Model-Based Nanoengineered Pharmacokinetics of Iron-Doped Copper Oxide for Nanomedical Applications. Angew Chem Int Ed Engl 2020;59:1828-36. [PMID: 31755189 DOI: 10.1002/anie.201912312] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
671 Rack S, Rahman R, Carter L, McKay C, Metcalf R. Impact of tumour profiling on clinical trials in salivary gland cancer. Clin Otolaryngol 2019;44:1-6. [PMID: 30102009 DOI: 10.1111/coa.13206] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
672 Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM Jr, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discov 2018;8:417-27. [PMID: 29431697 DOI: 10.1158/2159-8290.CD-17-1227] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 9.8] [Reference Citation Analysis]
673 Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016;6:1352-1365. [PMID: 27729313 DOI: 10.1158/2159-8290.cd-16-0050] [Cited by in Crossref: 129] [Cited by in F6Publishing: 82] [Article Influence: 21.5] [Reference Citation Analysis]
674 Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013;2:e22789. [PMID: 23482847 DOI: 10.4161/onci.22789] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 8.5] [Reference Citation Analysis]
675 Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget 2016;7:75839-53. [PMID: 27713119 DOI: 10.18632/oncotarget.12419] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
676 Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79-92. [PMID: 28050011 DOI: 10.1038/nrc.2016.126] [Cited by in Crossref: 338] [Cited by in F6Publishing: 307] [Article Influence: 67.6] [Reference Citation Analysis]
677 Lebrun H, Turpin A, Zerbib P. Therapeutic implications of B-RAF mutations in colorectal cancer. J Visc Surg 2021:S1878-7886(21)00059-X. [PMID: 33975809 DOI: 10.1016/j.jviscsurg.2021.04.002] [Reference Citation Analysis]
678 Schirripa M, Cohen SA, Battaglin F, Lenz HJ. Biomarker-driven and molecular targeted therapies for colorectal cancers. Semin Oncol 2018;45:124-32. [PMID: 30262397 DOI: 10.1053/j.seminoncol.2017.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
679 Garbe C, Abusaif S, Eigentler TK. Vemurafenib. Recent Results Cancer Res 2014;201:215-25. [PMID: 24756795 DOI: 10.1007/978-3-642-54490-3_13] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
680 Paul JM, Templeton SD, Baharani A, Freywald A, Vizeacoumar FJ. Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell. Trends Mol Med 2014;20:704-15. [PMID: 25446836 DOI: 10.1016/j.molmed.2014.09.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]